<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2405233723
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EPCLUSA 400 mg/100 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOFOSBUVIR,VELPATASVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400,100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40067.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GILEAD SCIENCES IRELAND UC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GILEAD SCIENCES IRELAND UC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gilead Sciences Ireland UC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AP55
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Epclusa is a medicine that contains the active substances sofosbuvir and velpatasvir in a single tablet.&nbsp; It is given to treat a chronic (long-term) viral infection of the liver called hepatitis&nbsp;C in patients aged 12 years and older or weighing at least 30 kg.</p><p>The active substances in this medicine work together by blocking two different proteins that the virus needs to grow and reproduce itself, allowing the infection to be permanently eliminated from the body.</p><p>It is very important that you also read the leaflets for the other medicines that you will be taking with Epclusa.&nbsp; If you have any questions about your medicines, please ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Epclusa</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong> to sofosbuvir, velpatasvir or any of the other ingredients of this medicine (listed in section 6 of this leaflet).</p><p>If this applies to you, <strong>do not take Epclusa and tell your doctor immediately.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are currently taking any of the following medicines:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin</strong> and <strong>rifabutin</strong> (antibiotics used to treat infections, including tuberculosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St.&nbsp;John&rsquo;s wort</strong> (herbal medicine used to treat depression);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine</strong>, <strong>phenobarbital</strong> and <strong>phenytoin</strong> (medicines used to treat epilepsy and prevent seizures);</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>have liver problems</strong> other than from hepatitis&nbsp;C, for instance</p><p style="margin-left:40px">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have a current or previous infection with the hepatitis&nbsp;B virus</strong><strong>,</strong> since your doctor may want to monitor you more closely;</p><p style="margin-left:40px">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have had a liver transplant</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>have kidney problems or if you are on kidney dialysis,</strong> since Epclusa has not been fully tested in patients with some severe kidney problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>are taking treatment for human immunodeficiency virus (HIV) infection,</strong> since your doctor may want to monitor you more closely.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Epclusa if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you currently take, or have taken in the last few months, the medicine amiodarone to treat irregular heartbeats, as it may result in a life-threatening slowing of your heart beat. Your doctor may consider alternative treatments if you have taken this medicine. If treatment with Epclusa is needed, you may require additional heart monitoring.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes. You may need closer monitoring of your blood glucose levels and/or adjustment of your diabetes medicines after starting Epclusa. Some diabetic patients have experienced low sugar levels in the blood (hypoglycaemia) after starting treatment with medicines like Epclusa.</p><p><strong>Tell your doctor immediately</strong> if you currently take, or have taken in the last months any medicines for heart problems and during treatment you experience:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow or irregular heartbeat, or heart rhythm problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath or worsening of existing shortness of breath;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light-headedness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; near fainting or fainting.</p><p><strong>Blood tests</strong></p><p>Your doctor will test your blood before, during and after your treatment with Epclusa.&nbsp; This is so that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor can decide if you should take Epclusa and for how long;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor can confirm that your treatment has worked and you are free of the hepatitis&nbsp;C virus.</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children under 12&nbsp;years of age and weighing less than 30 kg.</p><p>The use of Epclusa in patients under 12 years of age has not yet been established.</p><p><strong>Other medicines and Epclusa</strong></p><p><strong>Tell your doctor or pharmacist</strong> if you are taking, have recently taken or might take any other medicines.&nbsp;</p><p>Warfarin and other similar medicines called vitamin K antagonists are used to thin the blood.&nbsp; Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot.</p><p>Your liver function may change with treatment of hepatitis C and therefore may affect other medications (e.g. medicines used to suppress your immune system, etc.). Your doctor may need to closely monitor these other medicines you are taking and make adjustments after starting Epclusa.</p><p>If you are not sure talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Some medicines should not be taken with Epclusa.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not take any other medicine that contains sofosbuvir, one of the active substances in Epclusa.</strong></p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist</strong> if you are taking any of the medicines below:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>amiodarone</strong> used to treat irregular heartbeats;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifapentine </strong>(antibiotic used to treat infections, including tuberculosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>oxcarbazepine</strong> (medicine used to treat epilepsy and prevent seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tenofovir disoproxil fumarate</strong> or any medicine containing tenofovir disoproxil fumarate, used to treat HIV infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>efavirenz </strong>used to treat HIV infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>digoxin</strong> used to treat heart conditions;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>dabigatran </strong>used to thin the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>modafinil</strong> used to treat sleep disorders;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rosuvastatin</strong> or <strong>other statins</strong> used to treat high cholesterol.</p><p>Taking Epclusa with any of these may stop your medicines from working properly, or make any side effects worse.&nbsp; Your doctor may need to give you a different medicine or adjust the dose of medicine you are taking.&nbsp; This change could be to Epclusa or another medicine you are taking.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Get advice from a doctor or pharmacist</strong> if you take medicines used to treat <strong>stomach ulcers, heartburn or acid reflux </strong>as they can decrease the amount of velpatasvir in your blood<strong>.</strong>&nbsp; These medicines include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antacids (such as aluminium/magnesium hydroxide or calcium carbonate).&nbsp; These should be taken at least 4&nbsp;hours before or 4&nbsp;hours after Epclusa;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole).&nbsp; Epclusa should be taken with food 4 hours before using a proton pump inhibitor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; H<sub>2</sub>‑receptor antagonists (such as famotidine, cimetidine, nizatidine or ranitidine).&nbsp; If you need high doses of these medicines your doctor may give you a different medicine instead or adjust the dose of the medicine you are taking.</p><p>These medicines can decrease the amount of velpatasvir in your blood.&nbsp; If you are taking one of these medicines your doctor will either give you a different medicine for stomach ulcers, heartburn or acid reflux, or recommend how and when you take that medicine.</p><p><strong>Pregnancy and contraception</strong></p><p>The effects of Epclusa during pregnancy are not known.&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Epclusa is sometimes used together with ribavirin. &nbsp;Ribavirin can harm your unborn baby. &nbsp;It is therefore very important that you (or your partner) do not become pregnant during this treatment or for a period of time after completing treatment.&nbsp; You must read the &ldquo;Pregnancy&rdquo; section in the ribavirin package leaflet very carefully. &nbsp;Ask your doctor for effective contraception method suitable for you and your partner.</p><p><strong>Breast‑feeding</strong></p><p><strong>Do not breast‑feed during treatment with Epclusa.</strong>&nbsp; It is not known whether sofosbuvir or velpatasvir, the two active substances of Epclusa, pass into human breast milk.</p><p><strong>Driving and using machines</strong></p><p>Epclusa should not affect your ability to drive or use any tools or machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you.&nbsp; Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Recommended dose</strong></p><p>The recommended dose of Epclusa is <strong>one 400 mg/100 mg&nbsp;tablet once&nbsp;a&nbsp;day for 12&nbsp;weeks</strong>.</p><p>Swallow the tablet whole with or without food.&nbsp; Do not chew, crush or split the tablet as it has a very bitter taste.</p><p><strong>If you are taking an antacid</strong>, take it at least 4&nbsp;hours before or at least 4&nbsp;hours after Epclusa.</p><p><strong>If you are taking a proton pump inhibitor,</strong> take Epclusa with food 4 hours before using a proton pump inhibitor.</p><p><strong>If you are sick (vomit) after taking Epclusa</strong> it may affect the amount of Epclusa in your blood.&nbsp; This may make Epclusa work less well.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are sick (vomit) <strong>less than 3&nbsp;hours after</strong> taking Epclusa, take another tablet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are sick (vomit) <strong>more than 3&nbsp;hours after</strong> taking Epclusa, you do not need to take another tablet until your next scheduled tablet.</p><p><strong>If you take more Epclusa than you should</strong></p><p>If you accidentally take more than the recommended dose you should contact your doctor or nearest emergency department immediately for advice.&nbsp; Keep the tablet bottle with you so that you can easily describe what you have taken.</p><p><strong>If you forget to take Epclusa</strong></p><p>It is important not to miss a dose of this medicine.</p><p>If you do miss a dose, work out how long it is since you last took your Epclusa:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice within 18&nbsp;hours</strong> of the time you usually take Epclusa, you must take the tablet as soon as possible.&nbsp; Then take the next dose at your usual time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If it&rsquo;s 18&nbsp;hours or more</strong> after the time you usually take Epclusa, wait and take the next dose at your usual time.&nbsp; Do not take a double dose (two doses close together).</p><p><strong>Do not stop taking Epclusa</strong></p><p>Do not stop taking this medicine unless your doctor tells you to.&nbsp; It is very important that you complete the full course of treatment to give the medicine the best chance to treat your hepatitis&nbsp;C virus infection.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine may cause side effects, although not everybody gets them.<strong>&nbsp;</strong></p><p><strong>Common side effects</strong></p><p><em>(may affect up to&nbsp;1&nbsp;in 10&nbsp;people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p><strong>Uncommon side effects</strong></p><p><em>(may affect up to&nbsp;1&nbsp;in 100&nbsp;people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat (angioedema).</p><p><strong>Other effects that may be seen during treatment with sofosbuvir:</strong></p><p>The frequency of the following side effects is not known (frequency cannot be estimated from the available data).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a wide spread severe rash with peeling skin which may be accompanied by fever, flu like symptoms, blisters in the mouth, eyes, and/or genitals (Stevens Johnson syndrome).</p><p><strong>If you get any side effects tell your doctor.</strong></p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>If you get any side effects, talk to your doctor or pharmacist.</strong>&nbsp; This includes any possible side effects not listed in this leaflet.&nbsp; You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle and carton after &ldquo;EXP&rdquo;.&nbsp; The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste.&nbsp; Ask your pharmacist how to throw away medicines you no longer use.&nbsp; These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The active substances are</strong> sofosbuvir and velpatasvir.&nbsp; Each film‑coated tablet contains 400&nbsp;mg sofosbuvir and 100&nbsp;mg velpatasvir.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The other ingredients are</strong></p><p><em>Tablet core:</em></p><p>Copovidone, microcrystalline cellulose, croscarmellose sodium, magnesium stearate</p><p><em>Film‑coating:</em></p><p>Polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The film coated tablets are pink, diamond shaped tablets debossed with “GSI” on one side and “7916” on the other side.  The tablet is 20 mm long and 10 mm wide.

The following pack sizes are available for the 400 mg/100 mg film-coated tablets:
•	outer cartons containing 1 bottle of 28 film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gilead Sciences Ireland UC</p><p>IDA Business &amp; Technology Park</p><p>Carrigtohill</p><p>County Cork</p><p>Ireland</p><p>Tel: +353 (0) 21 483 5500</p><p>Fax: +353 (0) 21 483 5518</p><p>E mail: csafety@gilead.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2023

EUMAR21-ICGPS-AUG20-SAMAR23
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إيبكلوسا هو دواء يحتوي على المواد الفعالة سوفوسبوفير وفيلباتاسفير في قرص واحد. ويعطى لعلاج التهاب فيروسي مزمن (طويل الأجل) في الكبد يسمى التهاب الكبد C في المرضى بعمر 12 سنة وأكبر أو الذين يزنون 30 كلغ على الأقل.</p><p dir="RTL">المواد الفعالة في هذا الدواء تعمل معًا من خلال غلق اثنان من البروتينات المختلفة التي يحتاجها الفيروس لتنمو وتتكاثر في حد ذاته، والسماح للعدوى بأن يتم القضاء عليها نهائيًا من الجسم.</p><p dir="RTL">من المهم جدًا أن تقرأ أيضًا المنشورات الخاصة بالأدوية الأخرى التي سوف تؤخذ من إيبكلوسا. إذا كان لديك أي أسئلة حول أدويتك، فيرجى سؤال طبيبك أو الصيدلي عنها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول إيبكلوسا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp; إذا كانت لديك حساسية</strong> من سوفوسبوفير أو فيلباتاسفير أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 7 من هذه النشرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان هذا ينطبق عليك، <strong>فلا تتناول إيبكلوسا وأخبر طبيبك فورا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليًا أيًا من الأدوية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين و ريفابيوتين </strong>(مضادات حيوية مستعملة لعلاج العدوى، بما في ذلك السل)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> نبتة سانت جون</strong> (الأدوية العشبية المستعملة لعلاج الاكتئاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كاربامازيبين والفينوباربيتال والفينيتوين</strong> (الأدوية المستعملة في علاج الصرع ومنع النوبات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كان لديك مشاكل في الكبد</strong> عدا التهاب الكبد C، على سبيل المثال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كنت مصابًا حاليًا أو مسبقًا بفيروس التهاب الكبد B</strong>، حيث قد يرغب طبيبك في مراقبتك عن كثب؛</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت قد أجريت لك عملية زرع كبد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> كانت لديك مشاكل في الكلى أو إذا كنت تخضع للغسيل الكلوي</strong>، حيث إنه لم يتم اختبار إيبكلوسا بشكل كامل في المرضى الذين يعانون من بعض مشاكل حادة في الكلى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> كنت تتناول علاج لعدوى فيروس عوز المناعة البشرية (HIV)</strong>، حيث قد يرغب طبيبك في مراقبتك عن كثب.</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول إيبكلوسا إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول حاليًا أو قد تناولت في الأشهر القليلة الماضية دواء أميودارون amiodarone لعلاج عدم انتظام ضربات القلب، لأن هذا قد يؤدي إلى إبطاء معدل ضربات قلبك بشكل مهدد للحياة. قد ينظر طبيبك في علاجات بديلة إذا كنت قد تناولت هذا الدواء. إذا كان يلزم العلاج بإيبكلوسا، فقد تحتاج إلى مراقبة إضافية للقلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بداء السكري. قد تحتاج إلى مراقبة مستويات الجلوكوز في دمك عن كثب و/أو تعديل جرعات أدوية داء السكري الخاص بك بعد البدء في تناول إيبكلوسا. تعرض بعض المرضى الذين يعانون من داء السكري لانخفاض مستويات السكر في الدم (نقص جلوكوز الدم) بعد بدء العلاج بأدوية مثل إيبكلوسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك فورا</strong> إذا كنت تتناول حاليًا أو قد تناولت في الأشهر الماضية أي أدوية لمشاكل في القلب وعانيت خلال فترة العلاج من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;بطء أو عدم انتظام ضربات القلب أو مشاكل في نظم القلب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو تفاقم حالة ضيق تنفس تعاني منها بالفعل؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء الوشيك أو الإغماء.</p><p dir="RTL"><strong>إختبارات الدم</strong></p><p dir="RTL">سيقوم طبيبك باختبار دمك قبل وأثناء وبعد العلاج بإيبكلوسا، وهذا لكي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتمكن طبيبك من أن يقرر ما إذا كان يجب أن تتناول إيبكلوسا وإلى متى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتمكن طبيبك من أن يؤكد أن العلاج بدأ يعمل وأنك قد تحررت من فيروس التهاب الكبد C.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تعط هذا الدواء للأطفال تحت سن 12 سنة من العمر الذين يقل وزنهم عن 30 كلغ.</p><p dir="RTL">لم يتم بعد إثبات استعمال إيبكلوسا في المرضى الأصغر من 12 سنة.</p><p dir="RTL"><strong>الأدوية الأخرى وإيبكلوسا </strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي</strong> إذا كنت تتناول أو قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">الوارفارين وأدوية أخرى مماثلة تسمى مضادات فيتامين (ك) تستخدم لتخفيف الدم. قد يحتاج طبيبك إلى زيادة وتيرة فحوصات الدم لديك للتحقق من مدى تجلط الدم في دمك.</p><p dir="RTL">قد تتغير وظائف كبدك مع علاج التهاب الكبد C، وبالتالي قد يؤثر على الأدوية الأخرى (على سبيل المثال، الأدوية المستخدمة لتثبيط جهازك المناعي، إلخ.). قد يحتاج طبيبك إلى مراقبة تلك الأدوية الأخرى التي تتناولها عن كثب وإجراء تعديلات بعد بدء تناول إيبكلوسا.</p><p dir="RTL">إذا لم تكن متأكدًا فتحدث مع طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا ينبغي أن تؤخذ بعض الأدوية مع إيبكلوسا.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;لا تتناول العقار مع أي دواء آخر يحتوي على سوفوسبوفير، إحدى المواد الفعالة في إيبكلوسا.</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي</strong> إذا كنت تتناول أيا من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; أميودارون amiodarone</strong> يستعمل لعلاج عدم انتظام ضربات القلب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> ريفابينتاين rifapentine</strong> (مضاد حيوي يستعمل لعلاج الالتهابات، بما في ذلك السل)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> أوكسكاربازيبين oxcarbazepine</strong> (دواء يستعمل لعلاج الصرع ومنع النوبات)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; فومارات تينوفوفير دايزوبروكسيل tenofovir disoproxil fumarate</strong> أو أي دواء يحتوي على فومارات تينوفوفير دايزوبروكسيل، ويستعمل لعلاج العدوى بفيروس عوز المناعة البشرية والتهاب الكبد B المزمن؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إيفافيرنز efavirenz</strong> المستعمل لعلاج العدوى بفيروس عوز المناعة البشرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الديجوكسين digoxin</strong> ويستعمل لعلاج أمراض القلب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دابيغاتران dabigatran</strong> ويستعمل لتمييع الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مودافينيل modafinil</strong> ويستعمل لعلاج اضطرابات النوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>رسيوفاستاتين rosuvastatin أو الستاتينات الأخرى other statins</strong> (الأدوية الأخرى المخفضة للكوليسترول) المستعملة لعلاج ارتفاع الكوليسترول في الدم.</p><p dir="RTL">تناول إيبكلوسا مع أي من هذه الأدوية قد توقف دواءك عن العمل بشكل صحيح، أو جعل أي آثار جانبية أسوأ. قد يحتاج طبيبك لإعطائك دواءً آخر أو ضبط جرعة الدواء الذي تتناوله. يمكن أن يكون هذا التغيير في إيبكلوسا أو دواء آخر تتناوله</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp; احصل على المشورة من الطبيب أو الصيدلي</strong> إذا كنت تتناول أدوية تستعمل في علاج <strong>قرحة المعدة أو الحرقة أو حمض الجزر </strong>لأنها يمكن أن تقلل من كمية فيلباتاسفير في دمك. وتشتمل هذه الأدوية على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة (مثل هيدروكسيد الألومنيوم / المغنيسيوم أو كربونات الكالسيوم). ينبغي أن تؤخذ هذه قبل 4 ساعات أو بعد 4 ساعات من تناول إيبكلوسا؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات مضخة البروتون (مثل أوميبرازول، لانزوبرازول، الرابيبرازول، بانتوبرازول وإيسوميبرازول). ينبغي أن تؤخذ إيبكلوسا مع الطعام قبل 4 ساعات من تناول مثبطات مضخة البروتون؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات مستقبلات H<sub>2</sub> (مثل فاموتيدين، سيميتيدين، نيزاتيدين أو رانيتيدين). إذا كنت بحاجة إلى جرعات عالية من هذه الأدوية فإن طبيبك قد يعطيك دواءً مختلفًا بدلاً من ذلك، أو يضبط جرعة الدواء الذي تتناوله.</p><p dir="RTL">ويمكن لهذه الأدوية أن تقلل من كمية فيلباتاسفير في دمك. إذا كنت تتناول واحدًا من هذه الأدوية فقد يعطيك طبيبك دواءً مختلفًا لقرحة المعدة أو الحرقة أو حمض الجزر، أو يوصيك بكيفية تناول الدواء ووقته.</p><p dir="RTL"><strong>الحمل و وسائل منع الحمل</strong></p><p dir="RTL">إن تأثيرات إيبكلوسا ليست معروفة خلال فترة الحمل. إذا كنت حاملاً أو تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل، فاسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">يستعمل إيبكلوسا أحيانًا جنبًا إلى جنب مع ريبافيرين. يمكن أن يضر ريبافيرين طفلك الذي لم يولد بعد. ولذا فمن المهم جدًا أن لا تصبحي (أو شريك حياتك) حاملاً أثناء هذا العلاج أو لفترة من الوقت بعد الانتهاء من العلاج. يجب عليك قراءة قسم &quot;الحمل&quot; في نشرة العلبة التي تحتوي على ريبافيرين بعناية فائقة. اسألي طبيبك عن طريقة منع حمل فعالة مناسبة لك ولشريكك.</p><p>&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL"><strong>لا ترضعي طفلك طبيعيا أثناء العلاج ب</strong><strong>إيبكلوسا</strong>، لأنه من غير المعروف ما إذا كان سوفوسبوفير أو فيلباتاسفير، وهما من المواد الفعالة لإيبكلوسا، تنتقل إلى حليب الثدي البشري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وإستعمال الآلات</strong></p><p dir="RTL">يجب أن لا يؤثر إيبكلوسا على قدرتك على القيادة أو استخدام أي أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما قاله طبيبك لك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">الجرعة الموصى بها من إيبكلوسا هي <strong>قرص واحد 400 ملغم/100 ملغم مرة واحدة يوميًا لمدة 12&nbsp;أسبوعًا</strong>.</p><p dir="RTL">ابلع القرص بأكمله مع أو بدون طعام. لا تمضغ أو تسحق أو تقسم القرص لأن له طعمًا مرًا جدًا.</p><p dir="RTL"><strong>إذا كنت تتناول مضاد للحموضة</strong>، فتناوله بفترة لا تقل عن 4 ساعات قبل أو 4 ساعات بعد تناول إيبكلوسا.</p><p dir="RTL"><strong>إذا كنت تتناول دواء مثبط مضخة البروتون</strong>، فتناول إيبكلوسا مع الطعام قبل 4 ساعات من تناول مثبط مضخة البروتون.</p><p dir="RTL"><strong>إذا كنت قد تقيأت بعد تناول إيبكلوسا</strong>، فإن ذلك قد يؤثر على كمية إيبكلوسا في دمك. وهذا قد يجعل إيبكلوسا يعمل بشكل أقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تقيأت بعد أقل من 3 ساعات من تناول إيبكلوسا، فتناول قرصا آخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تقيأت بعد أكثر من 3 ساعات من تناول إيبكلوسا، فلا تحتاج إلى أخذ قرص آخر حتى موعد تناول القرص المجدول التالي.</p><p dir="RTL"><strong>إذا كنت قد تناولت إيبكلوسا أكثر مما يجب</strong></p><p dir="RTL">إذا كنت قد تناولت عن غير قصد أكثر من الجرعة الموصى بها يجب عليك الاتصال بطبيبك أو أقرب قسم للطوارئ على الفور للحصول على المشورة. احتفظ بالقنينة معك لكي تمكنك بسهولة من وصف ما كنت قد تناولته.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناول إيبكلوسا </strong></p><p dir="RTL">من المهم عدم تفويت جرعة من هذا الدواء.</p><p dir="RTL">إذا كنت قد نسيت تناول جرعة، فأحسب كم من الوقت مضى على آخر جرعة تناولتها من إيبكلوسا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا لاحظت ذلك في غضون 18 ساعة </strong>من الوقت الذي عادة ما تتناول فيه إيبكلوسا، فيجب أن تأخذ قرص آخر في أقرب وقت ممكن. ثم تناول الجرعة التالية في الوقت المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اذا كان ذلك 18 ساعة أو أكثر </strong>بعد الوقت الذي عادة ما تتناول فيه إيبكلوسا، فإنتظر وتناول الجرعة التالية في الوقت المعتاد. لا تتناول جرعة مضاعفة (جرعتين قريبة من بعضها البعض).</p><p dir="RTL"><strong>لا تتوقف عن تناول إيبكلوسا</strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء ما لم يخبرك طبيبك بذلك. من المهم جدا أن تكمل دورة كاملة من العلاج لإعطاء الدواء أفضل فرصة لعلاج التهاب الكبد C عندك.</p><p>إذا كان لديك أي أسئلة أخرى عن إستعمال هذا الدواء، فإسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، هذا الدواء قد يسبب آثارًا جانبية، على الرغم من أنها لا تحصل للجميع.</p><p dir="RTL"><strong>آثار جانبية شائعة</strong></p><p dir="RTL">(<em>قد تصيب ما يصل إلى 1 من بين كل 10 أشخاص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي<em>&nbsp;</em></p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL">(<em>قد تصيب ما يصل إلى 1 من بين كل 100 شخص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو اللسان أو الحلق (وذمة وعائية).</p><p dir="RTL"><strong>آثار أخرى قد تتم ملاحظتها أثناء العلاج بسوفوسبوفير:</strong></p><p dir="RTL">معدل تكرار الآثار الجانبية التالية غير معروف (لا يمكن تقدير معدل التكرار من البيانات المتاحة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد واسع الانتشار مع تقشر الجلد قد يصاحبه حمى وأعراض مشابهة للإنفلونزا وتقرحات في الفم و/أو العينين و/أو الأعضاء التناسلية (متلازمة ستيفنز جونسون).</p><p dir="RTL"><strong>&nbsp;إذا عانيت من أي آثار جانبية فأخبر طبيبك.&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><strong>إذا عانيت من أي آثار جانبية،</strong> <strong>فأخبر طبيبك أو الصيدلي</strong>. وهذه تشتمل على أي تأثيرات جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني.<strong> </strong>بإبلاغك عن الآثار الجانبية فإنك يمكن أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المثبت على القنينة والكارتون بعد كلمة &quot;EXP&quot;. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا يخزن في أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعمل. من شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي</strong> سوفوسبوفير و فيلباتاسفير. يحتوي كل قرص مغلف على 400 ملغم سوفوسبوفير و 100 ملغم فيلباتاسفير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي</strong></p><p dir="RTL"><em>لب القرص</em>:</p><p dir="RTL">كوبوفيدون Copovidone، السيلولوز البلوري المكروي، كروسكارميللوز الصوديوم، ستيرات المغنيسيوم</p><p dir="RTL"><em>طلاء تغليف القرص</em>:</p><p dir="RTL">الكحول البولي فينيل، ثاني أكسيد التيتانيوم، البولي إيثيلين غلايكول، التلك، وأكسيد الحديد الأحمر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل قرص </strong><strong>إيبكلوسا</strong><strong> وما هي محتويات العلبة</strong></p><p dir="RTL">الأقراص المغلفة بغشاء لونها وردي وعلى شكل ماسي مختوم عليها من جانب واحد الأحرف &quot;GSI&quot; و &quot;7916&quot; على الجانب الآخر. طول القرص هو 20 ملم وعرضه 10 ملم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر أحجام العلب التالية بالنسبة للأقراص بتركيز 400 ملغم/100 ملغم المغلفة بغشاء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كارتون خارجي فيه قنينة واحدة تحتوي على 28 قرصًا مغلفًا بغشاء</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>جيلياد للعلوم ايرلندا يو سي</p><p>حديقة &nbsp;آي دي أي للأعمال و التكنولوجيا</p><p>كاريغتوهيل</p><p>مقاطعة كورك</p><p>&nbsp;إيرلندا</p><p>الهاتف:<strong> </strong>+353 (0) 21 483 5500</p><p>الفاكس: +353 (0) 21 483 5518</p><p dir="RTL">البريد الإلكتروني:<strong> </strong>csafety@gilead.com</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2023

EUMAR21-ICGPS-AUG20-SAMAR23
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epclusa 400 mg/100 mg film coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 400 mg sofosbuvir and 100 mg velpatasvir.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.

Pink, diamond shaped, film coated tablet of dimensions 20 mm x 10 mm, debossed on one side with “GSI” and “7916” on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epclusa is indicated for the treatment of chronic hepatitis&nbsp;C virus (HCV) infection in patients aged 12 years and older or weighing at least 30 kg (see sections&nbsp;4.2,&nbsp;4.4 and&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epclusa treatment should be initiated and monitored by a physician experienced in the management of patients with HCV infection.</p><p><u>Posology</u></p><p>The recommended dose of Epclusa in adults is one 400&nbsp;mg/100&nbsp;mg tablet, taken orally, once daily with or without food (see section&nbsp;5.2).</p><p>The recommended dose of Epclusa in patients aged 12 to &lt;&nbsp;18 years or weighing at least 30 kg is one 400&nbsp;mg/100&nbsp;mg tablet, taken orally, once daily with or without food (see section&nbsp;5.2).</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Recommended treatment and duration for adults regardless of &nbsp;HCV genotype</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Adult patient population<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Treatment and duration</strong></p></td></tr></thead><tbody><tr><td><p>Patients without cirrhosis and patients with compensated cirrhosis</p></td><td><p>Epclusa for 12&nbsp;weeks</p><p><sup>&nbsp;</sup></p><p>Addition of ribavirin may be considered for genotype&nbsp;3 infected patients with compensated cirrhosis (see section&nbsp;5.1.)</p><p><sup>&nbsp;</sup></p></td></tr><tr><td><p>Patients with decompensated cirrhosis</p></td><td><p>Epclusa + ribavirin for 12&nbsp;weeks</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes patients co‑infected with human immunodeficiency virus (HIV) and patients with recurrent HCV post-liver transplant (see section&nbsp;4.4.)<em>.</em></p><p>&nbsp;</p><p>When used in combination with ribavirin, refer also to the Summary of Product Characteristics of the medicinal product containing ribavirin.</p><p>&nbsp;</p><p>The following dosing is recommended for adults where ribavirin is divided in two daily doses and given with food:</p><p><strong>Table&nbsp;2: Guidance for ribavirin dosing when administered with Epclusa to adults with decompensated cirrhosis</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adult patient </strong></p></td><td style="vertical-align:top"><p><strong>Ribavirin dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Child‑Pugh‑Turcotte (CPT) Class&nbsp;B cirrhosis pre-transplant</p></td><td style="vertical-align:top"><p>1,000&nbsp;mg per day for patients &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for those weighing &ge;&nbsp;75&nbsp;kg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CPT Class&nbsp;C cirrhosis pre-transplant</p><p>&nbsp;</p><p>CPT Class&nbsp;B or C post-transplant</p></td><td style="vertical-align:top"><p>Starting dose of 600&nbsp;mg, which can be titrated up to a maximum of 1,000/1,200&nbsp;mg (1,000&nbsp;mg for patients weighing &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for patients weighing &ge;&nbsp;75&nbsp;kg) if well tolerated.&nbsp; If the starting dose is not well tolerated, the dose should be reduced as clinically indicated based on haemoglobin levels</p></td></tr></tbody></table><p>If ribavirin is used in genotype&nbsp;3 infected adult patients with compensated cirrhosis (pre- or post-transplant) the recommended dose of ribavirin is 1,000/1,200&nbsp;mg (1,000&nbsp;mg for adult patients weighing &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for adult patients weighing &ge;&nbsp;75&nbsp;kg).</p><p>For ribavirin dose modifications, refer to the Summary of Product Characteristics of the medicinal product containing ribavirin.</p><p>&nbsp;</p><p>Patients should be instructed that if vomiting occurs within 3&nbsp;hours of dosing an additional tablet of Epclusa should be taken.&nbsp; If vomiting occurs more than 3&nbsp;hours after dosing, no further dose of Epclusa is needed (see section&nbsp;5.1).</p><p>If a dose of Epclusa is missed and it is within 18&nbsp;hours of the normal time, patients should be instructed to take the tablet as soon as possible and then patients should take the next dose at the usual time.&nbsp; If it is after 18&nbsp;hours then patients should be instructed to wait and take the next dose of Epclusa at the usual time.&nbsp; Patients should be instructed not to take a double dose of Epclusa.</p><p>&nbsp;</p><p><em>Adult patients who have previously failed therapy with an NS5A-containing regimen</em></p><p>Epclusa + ribavirin for 24&nbsp;weeks may be considered (see section&nbsp;4.4).</p><p><em>Elderly</em></p><p>No dose adjustment is warranted for elderly patients (see section&nbsp;5.2).</p><p><em>Renal impairment</em></p><p>No dose adjustment of Epclusa is required for patients with mild or moderate renal impairment.</p><p>Safety data are limited in patients with severe renal impairment (estimated glomerular filtration rate [eGFR]&nbsp;&lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) and end stage renal disease (ESRD) requiring haemodialysis. Epclusa can be used in these patients with no dose adjustment when no other relevant treatment options are available (see sections&nbsp;4.4, 5.1 and 5.2).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of Epclusa is required for patients with mild, moderate, or severe hepatic impairment (CPT Class&nbsp;A, B, or C) (see section&nbsp;5.2). &nbsp;Safety and efficacy of Epclusa have been assessed in patients with CPT Class&nbsp;B cirrhosis, but not in patients with CPT Class C cirrhosis (see sections&nbsp;4.4 and&nbsp;5.1).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Epclusa in children aged less than 12&nbsp;years and weighing less than 30 kg have not yet been established.</p><p><u>Method of administration</u></p><p>For oral use.</p><p>Patients should be instructed to swallow the tablet whole with or without food (see section&nbsp;5.2). &nbsp;Due to the bitter taste, it is recommended that the film‑coated tablet is not chewed or crushed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Medicinal products that are strong P glycoprotein (P-gp) and/or strong cytochrome P450 (CYP) inducers (carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin and St. John’s wort) (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epclusa should not be administered concurrently with other medicinal products containing sofosbuvir.</p><p><u>Severe bradycardia and heart block</u></p><p>Life-threatening cases of severe bradycardia and heart block have been observed when sofosbuvir-containing regimens are used in combination with amiodarone. Bradycardia has generally occurred within hours to days, but cases with a longer time to onset have been observed mostly up to 2 weeks after initiating HCV treatment.</p><p>Amiodarone should only be used in patients on Epclusa when other alternative anti-arrhythmic treatments are not tolerated or are contraindicated.</p><p>Should concomitant use of amiodarone be considered necessary, it is recommended that patients undergo cardiac monitoring in an in-patient setting for the first 48 hours of coadministration, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.</p><p>Due to the long half-life of amiodarone, cardiac monitoring as outlined above should also be carried out for patients who have discontinued amiodarone within the past few months and are to be initiated on Epclusa.</p><p>All patients with concurrent or recent use of amiodarone should be warned of the symptoms of bradycardia and heart block and should be advised to seek medical advice urgently should they experience them.</p><p><u>HCV/HBV (hepatitis&nbsp;B virus) co‑infection</u></p><p>Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents. HBV screening should be performed in all patients before initiation of treatment. HBV/HCV co-infected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current clinical guidelines.</p><p><u>Patients who have previously failed therapy with an NS5A-containing regimen</u></p><p>There are no clinical data to support the efficacy of sofosbuvir/velpatasvir for the treatment of patients who have failed treatment with a regimen containing another NS5A inhibitor. &nbsp;However, on the basis of NS5A resistance associated variants (RAVs) typically seen in patients who have failed therapy with other NS5A inhibitor containing regimens, the <em>in&nbsp;vitro</em> pharmacology of velpatasvir, and the outcomes of sofosbuvir/velpatasvir treatment in NS5A-na&iuml;ve patients with baseline NS5A RAVs enrolled into the ASTRAL-studies, treatment with Epclusa + RBV for 24&nbsp;weeks can be considered for patients who have failed therapy on an NS5A-containing regimen and who are deemed at high risk for clinical disease progression and who do not have alternative treatment options.</p><p><u>Renal impairment</u></p><p>Safety data are limited in patients with severe renal impairment (eGFR&nbsp;&lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) and ESRD requiring haemodialysis. Epclusa can be used in these patients with no dose adjustment when no other relevant treatment options are available (see sections&nbsp;5.1 and 5.2). When Epclusa is used in combination with ribavirin refer also to the Summary of Product Characteristics for ribavirin for patients with creatinine clearance &lt;&nbsp;50&nbsp;mL/min (see section&nbsp;5.2).</p><p><u>Use with moderate P‑gp inducers and/or moderate CYP inducers </u></p><p>Medicinal products that are moderate P-gp and/or moderate CYP inducers (e.g. efavirenz, modafinil, oxcarbazepine or rifapentine) may decrease sofosbuvir or velpatasvir plasma concentrations leading to reduced therapeutic effect of Epclusa. &nbsp;Co-administration of such medicinal products with Epclusa is not recommended (see section&nbsp;4.5).</p><p><u>Use with certain HIV antiretroviral regimens</u></p><p>Epclusa has been shown to increase tenofovir exposure, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat).&nbsp; The safety of tenofovir disoproxil fumarate in the setting of Epclusa and a pharmacokinetic enhancer has not been established. &nbsp;The potential risks and benefits associated with co‑administration of Epclusa with the fixed-dose combination tablet containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or tenofovir disoproxil fumarate given in conjunction with a boosted HIV protease inhibitor (e.g. atazanavir or darunavir) should be considered, particularly in patients at increased risk of renal dysfunction. &nbsp;Patients receiving Epclusa concomitantly with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for tenofovir‑associated adverse reactions. &nbsp;Refer to tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate Summary of Product Characteristics for recommendations on renal monitoring.</p><p><u>Use in diabetic patients </u></p><p>Diabetics may experience improved glucose control, potentially resulting in symptomatic hypoglycaemia, after initiating HCV direct-acting antiviral treatment. Glucose levels of diabetic patients initiating direct-acting antiviral therapy should be closely monitored, particularly within the first 3 months, and their diabetic medicines modified when necessary. The physician in charge of the diabetic care of the patient should be informed when direct-acting antiviral therapy is initiated.</p><p><u>CPT Class&nbsp;C cirrhosis</u></p><p>Safety and efficacy of Epclusa has not been assessed in patients with CPT Class&nbsp;C cirrhosis (see section&nbsp;5.1).</p><p><u>Liver transplant patients</u></p><p>The safety and efficacy of Epclusa in the treatment of HCV infection in patients who are post‑liver transplant have not been assessed.&nbsp; Treatment with Epclusa in accordance with the recommended posology (see section&nbsp;4.2) should be guided by an assessment of the potential benefits and risks for the individual patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Epclusa contains sofosbuvir and velpatasvir, any interactions that have been identified with these active substances individually may occur with Epclusa.</p><p><u>Potential for Epclusa to affect other medicinal products</u></p><p>Velpatasvir is an inhibitor of drug transporter P‑gp, breast cancer resistance protein (BCRP), organic anion‑transporting polypeptide (OATP)&nbsp;1B1 and OATP1B3. &nbsp;Co‑administration of Epclusa with medicinal products that are substrates of these transporters may increase the exposure of such medicinal products. &nbsp;See Table&nbsp;3 for examples of interactions with sensitive substrates of P-gp (digoxin), BCRP (rosuvastatin), and OATP (pravastatin).</p><p><u>Potential for other medicinal products to affect Epclusa </u></p><p>Sofosbuvir and velpatasvir are substrates of drug transporters P‑gp and BCRP.&nbsp; Velpatasvir is also a substrate of drug transporter OATP1B.&nbsp; <em>In&nbsp;vitro,</em> slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8 and CYP3A4 was observed. &nbsp;Medicinal products that are strong inducers of P‑gp and/or strong inducers of CYP2B6, CYP2C8, or CYP3A4 (e.g. carbamazepine, phenobarbital and phenytoin, rifampicin, rifabutin and St.&nbsp;John&rsquo;s wort) may decrease plasma concentrations of sofosbuvir or velpatasvir leading to reduced therapeutic effect of sofosbuvir/velpatasvir.&nbsp; The use of such medicinal products with Epclusa is contraindicated (see section&nbsp;4.3).&nbsp; Medicinal products that are moderate P‑gp&nbsp;inducers and/or moderate CYP inducers (e.g. efavirenz, modafinil, oxcarbazepine or rifapentine) may decrease sofosbuvir or velpatasvir plasma concentration leading to reduced therapeutic effect of Epclusa.&nbsp; Co‑administration with such medicinal products is not recommended with Epclusa (see section&nbsp;4.4). &nbsp;Co‑administration with medicinal products that inhibit P‑gp or BCRP may increase sofosbuvir or velpatasvir plasma concentrations.&nbsp; Medicinal products that inhibit OATP, CYP2B6, CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. &nbsp;Clinically significant medicinal product interactions with Epclusa mediated by P-gp, BCRP, OATP, or CYP450 inhibitors are not expected; Epclusa may be co‑administered with P‑gp, BCRP, OATP and CYP&nbsp;inhibitors.</p><p><u>Patients treated with vitamin K antagonists</u></p><p>As liver function may change during treatment with Epclusa, a close monitoring of International Normalised Ratio (INR) values is recommended.</p><p><u>Impact of DAA therapy on medicinal products metabolized by the liver</u></p><p>The pharmacokinetics of medicinal products that are metabolized by the liver (e.g. immunosuppressive agents such as calcineurin inhibitors) may be impacted by changes in liver function during DAA therapy, related to clearance of HCV.</p><p><u>Interactions between Epclusa and other medicinal products</u></p><p>Table&nbsp;3 provides a listing of established or potentially clinically significant medicinal product interactions (where 90% confidence interval [CI] of the geometric least‑squares mean [GLSM] ratio were within &ldquo;&harr;&rdquo;, extended above &ldquo;&uarr;&rdquo;, or extended below &ldquo;&darr;&rdquo; the predetermined interaction boundaries).&nbsp; The medicinal product interactions described are based on studies conducted with either sofosbuvir/velpatasvir or velpatasvir and sofosbuvir as individual agents, or are predicted medicinal product interactions that may occur with sofosbuvir/velpatasvir.&nbsp; The table is not all‑inclusive.</p><p><strong>Table&nbsp;3: Interactions between </strong><strong>Epclusa</strong> <strong>and other medicinal products</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p><strong>Medicinal product by therapeutic areas/Possible Mechanism of Interaction</strong></p></td><td colspan="14" style="vertical-align:bottom"><p><strong>Effects on medicinal product levels.</strong></p><p><strong>Mean ratio (90% confidence interval)</strong><strong><sup>a,b</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>Recommendation concerning co‑administration with Epclusa</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Active</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>C<sub>max</sub></strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>AUC</strong></p></td><td colspan="4" style="vertical-align:bottom"><p><strong>C<sub>min</sub></strong></p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ACID REDUCING AGENTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p></td><td colspan="14" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Velpatasvir solubility decreases as pH increases.&nbsp; Medicinal products that increase gastric pH are expected to decrease the concentration of velpatasvir.</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><em>Antacids</em></p></td></tr><tr><td style="vertical-align:top"><p>e.g. Aluminium or magnesium hydroxide; calcium carbonate</p><p>&nbsp;</p><p>(Increase in gastric pH)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected.</em></p><p>&harr; Sofosbuvir</p><p>&darr; Velpatasvir</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>It is recommended to separate antacid and Epclusa administration by 4&nbsp;hours.</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><em>H<sub>2</sub>‑receptor antagonists</em></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Famotidine</p><p>(40&nbsp;mg single dose)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg single dose)<sup>c</sup></p><p>&nbsp;</p><p>Famotidine dosed simultaneously with Epclusa<sup>d</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>Cimetidine<sup>e</sup></p><p>Nizatidine<sup>e</sup></p><p>Ranitidine<sup>e</sup></p><p><sup>&nbsp;</sup></p><p>(Increase in gastric pH)<sup> </sup></p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="4" style="vertical-align:top"><p>H<sub>2</sub>‑receptor antagonists may be administered simultaneously with or staggered from Epclusa at a dose that does not exceed doses comparable to famotidine 40&nbsp;mg twice daily.</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.80 (0.70, 0.91)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.81 (0.71, 0.91)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Famotidine</p><p>(40&nbsp;mg single dose)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg single dose)<sup>c</sup></p><p>&nbsp;</p><p>Famotidine dosed 12&nbsp;hours prior to Epclusa<sup>d</sup></p><p><sup>&nbsp;</sup></p><p>(Increase in gastric pH)</p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.77 (0.68, 0.87)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.80 (0.73, 0.88)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><em>Proton pump inhibitors</em></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Omeprazole</p><p>(20&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg single dose fasted)<sup>c</sup></p><p>&nbsp;</p><p>Omeprazole dosed simultaneously with Epclusa<sup>d</sup></p><p>&nbsp;</p><p>Lansoprazole<sup>e</sup></p><p>Rabeprazole<sup>e</sup></p><p>Pantoprazole<sup>e</sup></p><p>Esomeprazole<sup>e</sup></p><p><sup>&nbsp;</sup></p><p>(Increase in gastric pH)</p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.66 (0.55, 0.78)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.71 (0.60, 0.83)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p>Co-administration with proton pump inhibitors is not recommended. If it is considered necessary to co‑administer, then Epclusa should be administered with food and taken 4&nbsp;hours before proton pump inhibitor at max doses comparable to omeprazole 20&nbsp;mg.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.63 (0.50, 0.78)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.64 (0.52, 0.79)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Omeprazole</p><p>(20&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg single dose fed)<sup>c</sup></p><p>&nbsp;</p><p>Omeprazole dosed 4&nbsp;hours after Epclusa<sup>d</sup></p><p><sup>&nbsp;</sup></p><p>(Increase in gastric pH)</p></td><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.79 (0.68, 0.92)</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.67 (0.58, 0.78)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.74 (0.63, 0.86)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ANTIARRHYTHMICS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Amiodarone</p></td><td colspan="14" style="vertical-align:top"><p>Effect on amiodarone, velpatasvir, and sofosbuvir concentrations unknown.</p></td><td style="vertical-align:top"><p>Coadministration of amiodarone with a sofosbuvir containing regimen may result in serious symptomatic bradycardia.</p><p>Use only if no other alternative is available. Close monitoring is recommended if this medicinal product is administered with Epclusa (see sections&nbsp;4.4 and 4.8).</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin</p></td><td colspan="14" style="vertical-align:top"><p>Interaction only studied with velpatasvir.</p><p><em>Expected:</em></p><p>&harr; Sofosbuvir</p></td><td rowspan="3" style="vertical-align:top"><p>Co‑administration of Epclusa with digoxin may increase the concentration of digoxin. Caution is warranted and therapeutic concentration monitoring of digoxin is recommended when co‑administered with Epclusa.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Digoxin (0.25&nbsp;mg single dose)<sup>f</sup>/ velpatasvir (100&nbsp;mg single dose)</p><p>&nbsp;</p><p>(Inhibition of P‑gp)</p></td><td colspan="14" style="vertical-align:top"><p>Effect on velpatasvir exposure<s> </s>not studied</p><p><em>Expected:</em></p><p>&harr; Velpatasvir</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Observed:</em></p><p>Digoxin</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>1.9 (1.7, 2.1)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>1.3 (1.1, 1.6)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ANTICOAGULANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dabigatran etexilate</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(Inhibition of P‑gp)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&uarr; Dabigatran</p><p>&harr; Sofosbuvir</p><p>&harr; Velpatasvir</p></td><td style="vertical-align:top"><p>Clinical monitoring, looking for signs of bleeding and anaemia, is recommended when dabigatran etexilate is co-administered with Epclusa.&nbsp; A coagulation test helps to identify patients with an increased bleeding risk due to increased dabigatran exposure.</p></td></tr><tr><td style="vertical-align:top"><p>Vitamin K antagonists</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied</p></td><td style="vertical-align:top"><p>Close monitoring of INR is recommended with all vitamin K antagonists.&nbsp; This is due to liver function changes during treatment with Epclusa.</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ANTICONVULSANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p><p>Phenobarbital</p><p><strong><em>&nbsp;</em></strong></p><p>(Induction of P‑gp and</p><p>CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Sofosbuvir</p><p>&darr; Velpatasvir</p></td><td style="vertical-align:top"><p>Epclusa is contraindicated with phenobarbital and phenytoin (see section&nbsp;4.3).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Carbamazepine</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Velpatasvir</p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Epclusa is contraindicated with carbamazepine (see section&nbsp;4.3).</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Observed:</em></p><p>Sofosbuvir</p></td><td colspan="5" style="vertical-align:top"><p>&darr;0.52 (0.43, 0.62)</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&darr; 0.52 (0.46, 0.59)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oxcarbazepine</p><p>&nbsp;</p><p>&nbsp;</p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Sofosbuvir</p><p>&darr; Velpatasvir</p></td><td style="vertical-align:top"><p>Co‑administration of Epclusa with oxcarbazepine is expected to decrease the concentration of sofosbuvir and velpatasvir, leading to reduced therapeutic effect of Epclusa.&nbsp; Co‑administration is not recommended (see section&nbsp;4.4).</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ANTIFUNGALS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole</p></td><td colspan="14" style="vertical-align:top"><p>Interaction only studied with velpatasvir<strong><em> </em></strong></p><p><em>Expected:</em></p><p>&harr; Sofosbuvir</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of Epclusa or ketoconazole is required.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ketoconazole (200&nbsp;mg twice daily)/ velpatasvir (100&nbsp;mg single dose)<sup>d</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p>&nbsp;</p><p>(Inhibition of P‑gp and CYPs)</p><p>&nbsp;</p><p>Itraconazole<sup>e</sup></p><p>Voriconazole<sup>e</sup></p><p>Posaconazole<sup>e</sup></p><p>Isavuconazole<sup>e</sup></p></td><td colspan="14" style="vertical-align:top"><p>Effect on ketoconazole exposure not studied.</p><p><em>Expected:</em></p><p>&harr; Ketoconazole</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Observed:</em></p><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>1.3 (1.0, 1.6)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>1.7 (1.4, 2.2)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ANTIMYCOBACTERIALS</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rifampicin (600&nbsp;mg once daily)/ sofosbuvir (400&nbsp;mg single dose)<sup>d</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Effect on rifampicin exposure not studied.</p><p><em>&nbsp;</em></p><p><em>Expected:</em></p><p>&harr; Rifampicin</p></td><td rowspan="4" style="vertical-align:top"><p>Epclusa is contraindicated with rifampicin (see section&nbsp;4.3).</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Observed:</em></p><p>Sofosbuvir</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&darr;</p><p>0.23 (0.19, 0.29)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&darr;</p><p>0.28 (0.24, 0.32)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rifampicin (600&nbsp;mg once daily)/ velpatasvir (100&nbsp;mg single dose)</p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Effect on rifampicin exposure not studied.</p><p>&nbsp;</p><p><em>Expected:</em></p><p>&harr; Rifampicin</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Observed:</em></p><p>Velpatasvir</p><p><em>&nbsp;</em></p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.29 (0.23, 0.37)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.18 (0.15, 0.22)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rifabutin</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Velpatasvir</p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Epclusa is contraindicated with rifabutin (see section&nbsp;4.3).</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Observed:</em></p><p>Sofosbuvir</p></td><td colspan="6" style="vertical-align:top"><p>&darr;</p><p>0.64 (0.53, 0.77)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.76 (0.63, 0.91)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rifapentine</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Sofosbuvir</p><p>&darr; Velpatasvir</p></td><td style="vertical-align:top"><p>Co‑administration of Epclusa with rifapentine is expected to decrease the concentration of sofosbuvir and velpatasvir, leading to reduced therapeutic effect of Epclusa.&nbsp; Co‑administration is not recommended (see section&nbsp;4.4).</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>HIV ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Tenofovir disoproxil fumarate</p></td><td colspan="15" style="vertical-align:top"><p>Epclusa has been shown to increase tenofovir exposure (P-gp-inhibition).&nbsp; The increase in tenofovir exposure (AUC and C<sub>max</sub>) was around 40-80% during co-treatment with Epclusa and tenofovir disoproxil fumarate/emtricitabine as part of various HIV regimens.</p><p>&nbsp;</p><p>Patients receiving tenofovir disoproxil fumarate and Epclusa concomitantly should be monitored for adverse reactions associated with tenofovir disoproxil fumarate. Refer to the tenofovir disoproxil fumarate-containing product&rsquo;s Summary of Product Characteristics for recommendations on renal monitoring (see section&nbsp;4.4).</p><p><strong><em>&nbsp;</em></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Efavirenz/ emtricitabine/ tenofovir disoproxil fumarate</p><p>(600/ 200/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Efavirenz</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="3" style="vertical-align:top"><p>Co‑administration of Epclusa with efavirenz/ emtricitabine/ tenofovir disoproxil fumarate is expected to decrease the concentration of velpatasvir.&nbsp; Co‑administration of Epclusa with efavirenz‑containing regimens is not recommended (see section&nbsp;4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.4 (1.1, 1.7)</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.53 (0.43, 0.64)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.47 (0.39, 0.57)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.43 (0.36, 0.52)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Emtricitabine/ <strong>rilpivirine</strong>/ tenofovir disoproxil fumarate</p><p>(200/ 25/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Rilpivirine</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of Epclusa or emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate is required.</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>HIV ANTIVIRAL AGENTS: HIV PROTEASE INHIBITORS</em></strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Atazanavir</strong> boosted with ritonavir (300/ 100&nbsp;mg once daily)&nbsp;+&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200&nbsp;/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Atazanavir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.4 (1.2, 1.6)</p></td><td rowspan="4" style="vertical-align:top"><p>No dose adjustment of Epclusa, atazanavir (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ritonavir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.3 (1.5, 1.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.6 (1.4, 1.7)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>2.4 (2.2, 2.6)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>4.0 (3.6, 4.5)</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Darunavir</strong> boosted with ritonavir (800&nbsp;/ 100&nbsp;mg once daily)&nbsp;+&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Darunavir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="4" style="vertical-align:top"><p>No dose adjustment of Epclusa, darunavir (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ritonavir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.62 (0.54, 0.71)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.72 (0.66, 0.80)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.76 (0.65, 0.89)</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Lopinavir</strong> boosted with ritonavir&nbsp;(4x200&nbsp;mg/ 50&nbsp;mg once daily)&nbsp;+&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Lopinavir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="4" style="vertical-align:top"><p>No dose adjustment of Epclusa, lopinavir (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ritonavir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.59 (0.49 0.71)</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.7 (0.6, 0.8)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.70 (0.59, 0.83)</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.6 (1.4, 1.9)</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>HIV ANTIVIRAL AGENTS: INTEGRASE INHIBITORS</em></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Raltegravir </strong>(400&nbsp;mg twice daily)<sup>g</sup> +&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200&nbsp;/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Raltegravir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.79 (0.42, 1.5)</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of Epclusa, raltegravir or emtricitabine/ tenofovir disoproxil fumarate is required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Elvitegravir</strong>/ cobicistat/ emtricitabine/ tenofovir alafenamide fumarate</p><p>(150/ 150/ 200/ 10&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Elvitegravir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="5" style="vertical-align:top"><p>No dose adjustment of Epclusa or elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide fumarate is required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cobicistat</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>2.0 (1.7, 2.5)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Tenofovir alafenamide</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.4 (1.2, 1.5)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.3 (1.2, 1.5)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.5 (1.4, 1.7)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.6 (1.4, 1.8)</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Elvitegravir</strong>/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate</p><p>(150/ 150/ 200/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Elvitegravir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="4" style="vertical-align:top"><p>No dose adjustment of Epclusa or elvitegravir/ cobicistat/emtricitabine/ tenofovir disoproxil fumarate is required.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cobicistat</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.7 (1.5, 1.9)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.4 (1.2, 1.5)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Dolutegravir (50&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)</p></td><td colspan="2" style="vertical-align:top"><p>Dolutegravir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of Epclusa or dolutegravir is required.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>HERBAL SUPPLEMENTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>St.&nbsp;John&rsquo;s wort</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(Induction of P‑gp and CYPs)</p></td><td colspan="14" style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Sofosbuvir</p><p>&darr; Velpatasvir</p></td><td style="vertical-align:top"><p>Epclusa is contraindicated with St. John&rsquo;s wort (see section&nbsp;4.3).</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>HMG‑CoA REDUCTASE INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin (40&nbsp;mg single dose)&nbsp; + sofosbuvir / velpatasvir (400/ 100&nbsp; mg once daily)<sup>d</sup></p></td><td style="vertical-align:top"><p><em>Observed:</em></p><p>Atorvastatin</p></td><td colspan="7" style="vertical-align:top"><p>&uarr;</p><p>1.7</p><p>(1.5, 1.9)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.5</p><p>(1.5, 1.6)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment of Epclusa or atorvastatin is required.</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin</p></td><td colspan="14" style="vertical-align:top"><p>Interaction only studied with velpatasvir<em> </em></p><p><em>Expected:</em></p><p>&harr; Sofosbuvir</p><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Co‑administration of Epclusa with rosuvastatin increases the concentration of rosuvastatin, which is associated with increased risk of myopathy, including rhabdomyolysis.&nbsp; Rosuvastatin, at a dose that does not exceed 10&nbsp;mg, may be administered with Epclusa.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Rosuvastatin (10&nbsp;mg single dose)/ velpatasvir (100&nbsp;mg once daily)<sup>d</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p>(Inhibition of OATP1B and BCRP)</p></td><td colspan="5" style="vertical-align:top"><p><em>Observed:</em></p><p>Rosuvastatin</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>2.6 (2.3, 2.9)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>2.7 (2.5, 2.9)</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="14" style="vertical-align:top"><p>Effect on velpatasvir exposure not studied</p><p><em>Expected:</em></p><p>&harr; Velpatasvir</p></td></tr><tr><td style="vertical-align:top"><p>Pravastatin</p></td><td colspan="14" style="vertical-align:top"><p>Interaction only studied with velpatasvir<em> </em></p><p><em>Expected:</em></p><p>&harr; Sofosbuvir</p><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of Epclusa or pravastatin is required.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pravastatin (40&nbsp;mg single dose)/ velpatasvir (100&nbsp;mg once daily)<sup>d</sup></p><p><sup>&nbsp;</sup></p><p><sup>&nbsp;</sup></p><p>(Inhibition of OATP1B)</p></td><td colspan="2" style="vertical-align:top"><p><em>Observed:</em></p><p>Pravastatin</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>1.3 (1.1, 1.5)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>&uarr;</p><p>1.4 (1.2, 1.5)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="14" style="vertical-align:top"><p>Effect on velpatasvir exposure not studied</p><p><em>Expected:</em></p><p>&harr; Velpatasvir</p></td></tr><tr><td style="vertical-align:top"><p>Other statins</p></td><td colspan="14" style="vertical-align:top"><p><em>Expected:</em></p><p>&uarr; Statins</p></td><td style="vertical-align:top"><p>Interactions cannot be excluded with other HMG‑CoA reductase inhibitors. When co‑administered with Epclusa, careful monitoring for statin adverse reactions should be undertaken and a reduced dose of statins should be considered if required.</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>NARCOTIC ANALGESICS</em></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Methadone</p><p>(Methadone maintenance therapy [30 to 130&nbsp;mg daily])/ sofosbuvir (400&nbsp;mg once daily)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>R‑methadone</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>No dose adjustment of Epclusa or methadone is required.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>S‑methadone</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.3 (1.0, 1.7)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Methadone</p></td><td colspan="14" style="vertical-align:top"><p>Interaction only studied with sofosbuvir</p><p><em>Expected:</em></p><p>&harr; Velpatasvir</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>IMMUNOSUPPRESSANTS</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ciclosporin</p><p>(600&nbsp;mg single dose)/ sofosbuvir (400&nbsp;mg single dose)<sup>f</sup></p></td><td colspan="2" style="vertical-align:top"><p>Ciclosporin</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>No dose adjustment of Epclusa or ciclosporin is required at initiation of co-administration.&nbsp; Afterwards, close monitoring and potential dose adjustment of ciclosporin may be required.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>2.5 (1.9, 3.5)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>4.5 (3.3, 6.3)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ciclosporin</p><p>(600&nbsp;mg single dose)<sup>f</sup>/ velpatasvir (100&nbsp;mg single dose)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Ciclosporin</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.88 (0.78, 1.0)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Velpatasvir</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.6 (1.2, 2.0)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>2.0 (1.5, 2.7)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Tacrolimus</p><p>(5&nbsp;mg single dose)<sup>f</sup>/ sofosbuvir (400&nbsp;mg single dose)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Tacrolimus</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.73 (0.59, 0.90)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.1 (0.84, 1.4)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of Epclusa or tacrolimus is required at initiation of co-administration.&nbsp; Afterwards, close monitoring and potential dose adjustment of tacrolimus may be required.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sofosbuvir</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.97 (0.65, 1.4)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.1 (0.81, 1.6)</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus</p></td><td colspan="14" style="vertical-align:top"><p>Effect on velpatasvir exposure not studied.</p><p><em>Expected:</em></p><p>&harr; Velpatasvir</p></td></tr><tr><td colspan="16" style="vertical-align:top"><p><strong><em>ORAL CONTRACEPTIVES</em></strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Norgestimate/ ethinyl estradiol (norgestimate 0.180&nbsp;mg/ 0.215&nbsp;mg/ 0.25&nbsp;mg/ ethinyl estradiol 0.025&nbsp;mg)/ sofosbuvir (400&nbsp;mg once daily)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Norel-gestromin</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>No dose adjustment of oral contraceptives is required.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Norgestrel</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.2 (0.98, 1.5)</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.2 (1.0, 1.5)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ethinyl estradiol</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Norgestimate/ ethinyl estradiol (norgestimate 0.180&nbsp;mg/ 0.215&nbsp;mg/ 0.25&nbsp;mg/ ethinyl estradiol 0.025&nbsp;mg)/ velpatasvir (100&nbsp;mg once daily)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>Norel-gestromin</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Norgestrel</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ethinyl estradiol</p></td><td colspan="4" style="vertical-align:top"><p>&uarr;</p><p>1.4 (1.2, 1.7)</p></td><td colspan="4" style="vertical-align:top"><p>&harr;</p><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&darr;</p><p>0.83 (0.65, 1.1)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean ratio (90%&nbsp;CI) of co‑administered drug pharmacokinetics of study medicinal products alone or in combination.&nbsp; No effect&nbsp;=&nbsp;1.00.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All interaction studies conducted in healthy volunteers.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administered as Epclusa.</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of pharmacokinetics interaction bounds 70‑143%.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These are medicinal products within class where similar interactions could be predicted.</p><p>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bioequivalence/Equivalence boundary 80‑125%.</p><p>g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Lack of pharmacokinetics interaction bounds 50-200%</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data (less than 300&nbsp;pregnancy outcomes) from the use of sofosbuvir, velpatasvir or Epclusa in pregnant women.</p><p><u>Sofosbuvir</u></p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>It has not been possible to fully estimate exposure margins achieved for sofosbuvir in the rat relative to the exposure in humans at the recommended clinical dose (see section&nbsp;5.3).</p><p><u>Velpatasvir</u></p><p>Animal studies have shown a possible link to reproductive toxicity (see section&nbsp;5.3).</p><p>As a precautionary measure, Epclusa use is not recommended during pregnancy.</p><p><u>Breast‑feeding</u></p><p>It is unknown whether sofosbuvir, metabolites of sofosbuvir or velpatasvir are excreted in human milk.</p><p>Available pharmacokinetic data in animals have shown excretion of velpatasvir and metabolites of sofosbuvir in milk.</p><p>A risk to the newborns/infants cannot be excluded.&nbsp; Therefore, Epclusa should not be used during breast‑feeding.</p><p><u>Fertility</u></p><p>No human data on the effect of Epclusa on fertility are available.&nbsp; Animal studies do not indicate harmful effects of sofosbuvir or velpatasvir on fertility.</p><p>If ribavirin is co‑administered with Epclusa, refer to the Summary of Product Characterisitics for ribavirin for detailed recommendations regarding pregnancy, contraception, and breast‑feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epclusa has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of Epclusa has been determined in pooled Phase&nbsp;3 clinical studies of patients with genotype&nbsp;1, 2, 3, 4, 5 or 6 HCV infection and in the postmarketing setting. No adverse drug reactions to Epclusa were identified from clinical trials. In the postmarketing setting, cases of severe bradycardia and heart block have been observed when SOF-containing products are used in combination with amiodarone, and HBV reactivation has been observed in patients coinfected with HCV/HBV following treatment with DAAs (see section 4.4).</p><p><u>Tabulated summary of adverse reactions</u></p><p>Assessment of adverse reactions for Epclusa is based on safety data from clinical studies and postmarketing experience. All adverse reactions are presented in Table&nbsp;4. The adverse reactions are listed below by system organ class and frequency.&nbsp; Frequencies are defined as follows: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1000) or very rare (&lt;&nbsp;1/10,000).</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Adverse drug reactions identified with Epclusa</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:395px"><thead><tr><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse drug reaction</strong></p></td></tr></thead><tbody><tr><td colspan="2"><p><em>Skin and subcutaneous tissue disorders:</em></p></td></tr><tr><td><p>Common</p></td><td><p>rash<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>angioedema<sup>a</sup></p></td></tr></tbody></table><p>a. Adverse reaction identified through post-marketing surveillance for sofosbuvir/velpatasvir-containing products</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Cardiac arrhythmias</em></p><p>Cases of severe bradycardia and heart block have been observed when sofosbuvir-containing regimens are used in combination with amiodarone and/or other medicinal products that lower heart rate (see sections&nbsp;4.4 and&nbsp;4.5).</p><p><em>Skin disorders</em></p><p>Frequency not known: Stevens-Johnson syndrome</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety assessment of Epclusa in paediatric patients aged 12 years and older is based on data from a Phase 2, open-label clinical study (Study&nbsp;1143) that enrolled 102 patients who were treated with sofosbuvir/velpatasvir for 12 weeks. The adverse reactions observed were consistent with those observed in clinical studies of Epclusa in adults.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important.&nbsp; It allows continued monitoring of the benefit/risk balance of the medicinal product. &nbsp;Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:-19.6pt;margin-top:3.4pt;width:477.45pt;height:60.55pt;z-index:251657728;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_2;
  mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest documented doses of sofosbuvir and velpatasvir were a single dose of 1,200&nbsp;mg and a single dose of 500&nbsp;mg, respectively.&nbsp; In these healthy adult volunteer studies, there were no untoward effects observed at these dose levels. The effects of higher doses/exposures are not known.</p><p>&nbsp;</p><p>No specific antidote is available for overdose with Epclusa. &nbsp;If overdose occurs the patient must be monitored for evidence of toxicity. &nbsp;Treatment of overdose with Epclusa consists of general supportive measures including monitoring of vital signs, as well as observation of the clinical status of the patient. &nbsp;Haemodialysis can efficiently remove the predominant circulating metabolite of sofosbuvir, GS‑331007, with an extraction ratio of 53%.&nbsp; Haemodialysis is unlikely to result in significant removal of velpatasvir, since velpatasvir is highly bound to plasma protein.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use; Direct acting antiviral, ATC code: J05AP55</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Sofosbuvir is a pan‑genotypic inhibitor of the HCV NS5B RNA‑dependent RNA&nbsp;polymerase, which is essential for viral replication.&nbsp; Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analogue triphosphate (GS‑461203), which can be incorporated into HCV&nbsp;RNA by the NS5B&nbsp;polymerase and acts as a chain terminator.&nbsp; GS‑461203 (the active metabolite of sofosbuvir) is neither an inhibitor of human DNA and RNA&nbsp;polymerases nor an inhibitor of mitochondrial RNA&nbsp;polymerase.</p><p>Velpatasvir is a HCV inhibitor targeting the HCV&nbsp;NS5A protein, which is essential for both RNA replication and the assembly of HCV virions. &nbsp;<em>In&nbsp;vitro</em> resistance selection and cross-resistance studies indicate velpatasvir targets NS5A as its mode of action.</p><p>&nbsp;</p><p><u>Antiviral activity</u></p><p>The 50% effective concentration (EC<sub>50</sub>) values of sofosbuvir and velpatasvir against full‑length or chimeric replicons encoding NS5B and NS5A sequences from the laboratory strains are presented in Table&nbsp;5. &nbsp;The EC<sub>50</sub> values of sofosbuvir and velpatasvir against clinical isolates are presented in Table&nbsp;6.</p><p>&nbsp;</p><p><strong>Table&nbsp;5: Activity of sofosbuvir and velpatasvir against full‑length or chimeric laboratory replicons</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Replicon genotype</strong></p></td><td style="vertical-align:top"><p><strong>Sofosbuvir EC<sub>50</sub>, nM<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Velpatasvir EC<sub>50</sub>, nM<sup>a</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>1a</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0.014</p></td></tr><tr><td style="vertical-align:top"><p>1b</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>0.016</p></td></tr><tr><td style="vertical-align:top"><p>2a</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>0.005‑0.016<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>2b</p></td><td style="vertical-align:top"><p>15<sup>b</sup></p></td><td style="vertical-align:top"><p>0.002‑0.006<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>3a</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>4a</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0.009</p></td></tr><tr><td style="vertical-align:top"><p>4d</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>5a</p></td><td style="vertical-align:top"><p>15<sup>b</sup></p></td><td style="vertical-align:top"><p>0.021‑0.054<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>6a</p></td><td style="vertical-align:top"><p>14<sup>b</sup></p></td><td style="vertical-align:top"><p>0.006‑0.009</p></td></tr><tr><td style="vertical-align:top"><p>6e</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>0.130<sup>d</sup></p></td></tr></tbody></table><p>NA&nbsp;=&nbsp;Not available</p><p>a&nbsp; &nbsp;Mean value from multiple experiments of same laboratory replicon.</p><p>b&nbsp; &nbsp;Stable chimeric 1b replicons carrying NS5B genes from genotype&nbsp;2b, 5a or 6a were used for testing.</p><p>c&nbsp; &nbsp;Data from various strains of full length NS5A replicons or chimeric NS5A replicons carrying full‑length NS5A genes that contain L31 or M31 polymorphisms.</p><p>d&nbsp; &nbsp;Data from a chimeric NS5A replicon carrying NS5A amino acids 9‑184.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Activity of sofosbuvir and velpatasvir against transient replicons containing NS5A or NS5B from clinical isolates</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>Replicon genotype</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Replicons containing NS5B from clinical isolates</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Replicons containing NS5A from clinical isolates</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of clinical isolates</strong></p></td><td style="vertical-align:top"><p><strong>Median sofosbuvir EC<sub>50</sub>, nM (range)</strong></p></td><td style="vertical-align:top"><p><strong>Number of clinical isolates</strong></p></td><td style="vertical-align:top"><p><strong>Median velpatasvir EC<sub>50</sub>, nM (range)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>1a</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>62 (29‑128)</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0.019 (0.011‑0.078)</p></td></tr><tr><td style="vertical-align:top"><p>1b</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>102 (45‑170)</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0.012 (0.005‑0.500)</p></td></tr><tr><td style="vertical-align:top"><p>2a</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>29 (14‑81)</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.011 (0.006‑0.364)</p></td></tr><tr><td style="vertical-align:top"><p>2b</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.002 (0.0003‑0.007)</p></td></tr><tr><td style="vertical-align:top"><p>3a</p></td><td style="vertical-align:top"><p>106</p></td><td style="vertical-align:top"><p>81 (24‑181)</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>0.005 (0.002‑1.871)</p></td></tr><tr><td style="vertical-align:top"><p>4a</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0.002 (0.001‑0.004)</p></td></tr><tr><td style="vertical-align:top"><p>4d</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.007 (0.004‑0.011)</p></td></tr><tr><td style="vertical-align:top"><p>4r</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0.003 (0.002‑0.006)</p></td></tr><tr><td style="vertical-align:top"><p>5a</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>0.005 (0.001‑0.019)</p></td></tr><tr><td style="vertical-align:top"><p>6a</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.007 (0.0005‑0.113)</p></td></tr><tr><td style="vertical-align:top"><p>6e</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.024 (0.005‑0.433)</p></td></tr></tbody></table><p>NA&nbsp;=&nbsp;Not available</p><p>&nbsp;</p><p>The presence of 40% human serum had no effect on the anti‑HCV activity of sofosbuvir but reduced the anti‑HCV activity of velpatasvir by 13‑fold against genotype&nbsp;1a HCV replicons.</p><p>Evaluation of sofosbuvir in combination with velpatasvir showed no antagonistic effect in reducing HCV&nbsp;RNA levels in replicon cells.</p><p>&nbsp;</p><p><u>Resistance</u></p><p><em>In cell culture</em></p><p>HCV replicons with reduced susceptibility to sofosbuvir have been selected in cell culture for multiple genotypes including 1b, 2a, 2b, 3a, 4a, 5a and 6a.&nbsp; Reduced susceptibility to sofosbuvir was associated with the primary NS5B substitution S282T in all replicon genotypes examined.&nbsp; Site-directed mutagenesis of the S282T substitution in replicons of genotype&nbsp;1 to 6 conferred 2‑ to 18‑fold reduced susceptibility to sofosbuvir and reduced the replication viral capacity by 89% to 99% compared to the corresponding wild-type.&nbsp; In biochemical assays, the ability of the active triphosphate of sofosbuvir (GS‑461203) to inhibit recombinant NS5B polymerase from genotypes&nbsp;1b, 2a, 3a and 4a expressing the S282T substitution was reduced compared to its ability to inhibit wild-type recombinant NS5B polymerase, as indicated by a 8.5‑ to 24‑fold increase in the 50% inhibitory concentration (IC<sub>50</sub>).</p><p><em>In&nbsp;vitro</em> selection of HCV replicons with reduced susceptibility to velpatasvir was performed in cell culture for multiple genotypes including 1a, 1b, 2a, 3a, 4a, 5a and 6a.&nbsp; Variants were selected at NS5A resistance associated positions 24, 28, 30, 31, 32, 58, 92 and 93. &nbsp;The resistance associated variants (RAVs) selected in 2 or more genotypes were F28S, L31I/V and Y93H.&nbsp; Site-directed mutagenesis of known NS5A&nbsp;RAVs showed that substitutions conferring a &gt;&nbsp;100‑fold reduction in velpatasvir susceptibility are M28G, A92K and Y93H/N/R/W in genotype&nbsp;1a, A92K in genotype&nbsp;1b, C92T and Y93H/N in genotype&nbsp;2b, Y93H in genotype&nbsp;3, and L31V and P32A/L/Q/R in genotype&nbsp;6.&nbsp; No individual substitutions tested in genotypes&nbsp;2a, 4a, or 5a conferred a &gt;&nbsp;100‑fold reduction in velpatasvir susceptibility. &nbsp;Combinations of these variants often showed greater reductions in susceptibility to velpatasvir than single RAVs alone.</p><p>&nbsp;</p><p><em>In clinical studies</em></p><p><em>Studies in patients without cirrhosis and patients with compensated cirrhosis</em></p><p>In a pooled analysis of patients without cirrhosis or with compensated cirrhosis who received Epclusa for 12&nbsp;weeks in three Phase&nbsp;3 studies, 12&nbsp;patients (2 with genotype&nbsp;1 and 10 with genotype&nbsp;3) qualified for resistance analysis due to virologic failure.&nbsp; One additional patient with genotype&nbsp;3 HCV infection at baseline was reinfected with genotype&nbsp;1a HCV at virologic failure and was excluded from the virological analysis.&nbsp; No patients with genotype&nbsp;2, 4, 5, or 6 HCV infection experienced virologic failure.</p><p>Of the 2 genotype&nbsp;1 virologic failure patients, one patient had virus with emergent NS5A&nbsp;RAV Y93N and the other patient had virus with emergent NS5A&nbsp;RAVs L31I/V and Y93H at virologic failure. &nbsp;Both patients had virus at baseline harboring NS5A&nbsp;RAVs.&nbsp; No NS5B nucleoside inhibitor (NI) RAVs were observed at failure in the 2&nbsp;patients.</p><p>Of the 10 genotype&nbsp;3 virologic failure patients, Y93H was observed in all 10&nbsp;patients at failure (6 had Y93H emerge post-treatment and 4&nbsp;patients had Y93H at baseline and post-treatment).&nbsp; No NS5B&nbsp;NI&nbsp;RAVs were observed at failure in the 10&nbsp;patients.</p><p>&nbsp;</p><p><em>Studies in patients with decompensated cirrhosis</em></p><p>In one Phase&nbsp;3 study in patients with decompensated cirrhosis who received Epclusa + RBV for 12&nbsp;weeks, 3&nbsp;patients (1 with genotype&nbsp;1 and 2 with genotype&nbsp;3) qualified for resistance analysis due to virologic failure.&nbsp; No patients with genotype&nbsp;2 or 4 HCV infection in the Epclusa + RBV 12&nbsp;weeks group experienced virologic failure.</p><p>The 1 virologic failure patient with genotype&nbsp;1 HCV had no NS5A or NS5B&nbsp;RAVs at failure.</p><p>Of the 2 genotype&nbsp;3 virologic failure patients, one had NS5A&nbsp;RAV Y93H emerge at failure.&nbsp; Another patient had virus with Y93H at baseline and virologic failure and also developed low levels (&lt;&nbsp;5%) of NS5B&nbsp;NI&nbsp;RAVs N142T and E237G at failure.&nbsp; Pharmacokinetic data from this patient was consistent with non-adherence to treatment.</p><p>In this study, 2&nbsp;patients treated with Epclusa for 12 or 24&nbsp;weeks without ribavirin had emergent NS5B S282T at low levels (&lt;&nbsp;5%) along with L159F.</p><p>&nbsp;</p><p><u>Effect of baseline HCV resistance-associated variants on treatment outcome</u></p><p><em>Studies in patients without cirrhosis and patients with compensated cirrhosis</em></p><p>Analyses were conducted to explore the association between pre-existing baseline NS5A&nbsp;RAVs and treatment outcome for patients without cirrhosis or with compensated cirrhosis in three Phase&nbsp;3 clinical studies (ASTRAL‑1, ASTRAL‑2 and ASTRAL‑3).&nbsp; Of the 1,035&nbsp;patients treated with sofosbuvir/velpatasvir in the three Phase&nbsp;3 clinical studies, 1,023&nbsp;patients were included in the analysis of NS5A&nbsp;RAVs; 7&nbsp;patients were excluded as they neither achieved sustained virologic response (SVR12) nor had virologic failure and 5&nbsp;additional patients were excluded as NS5A gene sequencing failed.&nbsp; In the pooled analysis of the Phase&nbsp;3 studies, 380/1,023 (37%) patients&rsquo; virus had baseline NS5A&nbsp;RAVs.&nbsp; Genotype&nbsp;2, 4, and 6 HCV‑infected patients had a higher prevalence of NS5A&nbsp;RAVs (70%, 63% and 52%, respectively) compared to genotype&nbsp;1 (23%), genotype&nbsp;3 (16%), and genotype&nbsp;5 (18%) HCV‑infected patients.</p><p>Baseline RAVs had no relevant impact on SVR12 rates in patients infected with genotype 1, 2, 4, 5 and 6 HCV, as summarised in Table&nbsp;7. &nbsp;Genotype&nbsp;3 infected patients with the NS5A RAV Y93H at baseline had a lower SVR12 rate than patients without Y93H after treatment with Epclusa for 12&nbsp;weeks, as summarised in Table&nbsp;8. &nbsp;In the ASTRAL-3 study, the Y93H RAV was detected at baseline in 9% of patients treated with Epclusa.</p><p>&nbsp;</p><p><strong>Table&nbsp;7: SVR12 in patients with or without baseline NS5A&nbsp;RAVs by HCV genotype (studies ASTRAL‑1, ASTRAL‑2 and ASTRAL‑3)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Epclusa 12&nbsp;weeks</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;1</strong></p></td><td style="vertical-align:top"><p><strong>Genotype&nbsp;3</strong></p></td><td style="vertical-align:top"><p><strong>Genotypes&nbsp;2, 4, 5 or 6</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p></td></tr></thead><tbody><tr><td><p>With any baseline NS5A&nbsp;RAVs</p></td><td><p>97% (73/75)</p></td><td><p>88% (38/43)</p></td><td><p>100% (262/262)</p></td><td><p>98% (373/380)</p></td></tr><tr><td><p>Without baseline NS5A&nbsp;RAVs</p></td><td><p>100% (251/251)</p></td><td><p>97% (225/231)</p></td><td><p>100% (161/161)</p></td><td><p>99% (637/643)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;8: SVR12 in patients with and without baseline Y93H, 1% Cut-off (Resistance Analysis Population Set) ASTRAL 3</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:608px"><tbody><tr><td rowspan="2" style="vertical-align:bottom">&nbsp;</td><td colspan="3"><p><strong>Epclusa 12 Weeks</strong></p></td></tr><tr><td><p><strong>All Subjects</strong></p><p><strong>(n = 274)</strong></p></td><td><p><strong>Cirrhotic</strong></p><p><strong>(n = 80)</strong></p></td><td><p><strong>Non-Cirrhotic</strong></p><p><strong>(n = 197)</strong></p></td></tr><tr><td><p>Overall</p></td><td><p>95.3% (263/274)</p></td><td><p>91.3% (73/80)</p></td><td><p>97.9% (190/194)</p></td></tr><tr><td><p>95% CI</p></td><td><p>92.9% to 98.0%</p></td><td><p>82.8% to 96.4%</p></td><td><p>92.8% to 98.6%</p></td></tr><tr><td><p>SVR with Y93H</p></td><td><p>84.0% (21/25)</p></td><td><p>50.0% (2/4)</p></td><td><p>90.5% (19/21)</p></td></tr><tr><td><p>95% CI</p></td><td><p>63.9% to 95.5%</p></td><td><p>6.8% to 93.2%</p></td><td><p>69.6% to 98.8%</p></td></tr><tr><td><p>SVR without Y93H</p></td><td><p>96.4% (242/249)</p></td><td><p>93.4% (71/76)</p></td><td><p>98.8% (171/173)</p></td></tr><tr><td><p>95% CI</p></td><td><p>94.3% to 98.9%</p></td><td><p>85.3% to 97.8%</p></td><td><p>95.9% to 99.9%</p></td></tr></tbody></table><p>&nbsp;</p><p>The NS5B NI RAV S282T was not detected in the baseline NS5B sequence of any patient in Phase&nbsp;3 studies.&nbsp; SVR12 was achieved in all 77&nbsp;patients who had baseline NS5B&nbsp;NI&nbsp;RAVs including N142T, L159F, E/N237G, C/M289L/I, L320F/I/V, V321A/I, and S282G+V321I.</p><p>&nbsp;</p><p><em>Studies in patients with decompensated cirrhosis (CPT Class&nbsp;B)</em></p><p>Analyses were conducted to explore the association between pre-existing baseline NS5A&nbsp;RAVs and treatment outcome for patients with decompensated cirrhosis in one Phase&nbsp;3 study (ASTRAL‑4).&nbsp; Of the 87&nbsp;patients treated with Epclusa + RBV, 85&nbsp;patients were included in the analysis of NS5A&nbsp;RAVs; 2&nbsp;patients were excluded as they neither achieved SVR12 nor had virologic failure.&nbsp; Among the patients who received treatment with Epclusa + RBV for 12&nbsp;weeks, 29% (25/85) of patients had baseline virus with NS5A&nbsp;RAVs: 29% (19/66), 75% (3/4), 15% (2/13), and 50% (1/2) for patients with genotype&nbsp;1, 2, 3 and 4 HCV, respectively.</p><p>&nbsp;</p><p>SVR12 in patients with or without baseline NS5A&nbsp;RAVs in the Epclusa + RBV 12&nbsp;week group for this study is shown in Table&nbsp;9.</p><p><strong>Table&nbsp;9: SVR12 in patients with or without baseline NS5A&nbsp;RAVs by HCV genotype (study ASTRAL‑4)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Epclusa + RBV 12&nbsp;weeks</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;1</strong></p></td><td style="vertical-align:top"><p><strong>Genotype&nbsp;3</strong></p></td><td style="vertical-align:top"><p><strong>Genotypes&nbsp;2 or 4</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p></td></tr></thead><tbody><tr><td><p>With any baseline NS5A&nbsp;RAVs</p></td><td><p>100% (19/19)</p></td><td><p>50% (1/2)</p></td><td><p>100% (4/4)</p></td><td><p>96% (24/25)</p></td></tr><tr><td><p>Without baseline NS5A&nbsp;RAVs</p></td><td><p>98% (46/47)</p></td><td><p>91% (10/11)</p></td><td><p>100% (2/2)</p></td><td><p>98% (58/60)</p></td></tr></tbody></table><p>&nbsp;</p><p>The single genotype&nbsp;3 patient who had baseline NS5A&nbsp;RAVs and failed to achieve SVR12 had NS5A substitution Y93H at baseline; pharmacokinetic data from this patient was consistent with non‑adherence to treatment.</p><p>Three patients in the Epclusa + RBV 12&nbsp;week group had baseline NS5B&nbsp;NI&nbsp;RAVs (N142T and L159F) and all three patients achieved SVR12.</p><p><u>Paediatric population</u></p><p>The presence of NS5A and NS5B RAVs did not impact treatment outcome in Study 1143; all patients with baseline NS5A (n=16) or NS5B NI (n=5) RAVs achieved SVR following 12 weeks treatment with Epclusa.</p><p><u>Cross‑resistance</u></p><p><em>In&nbsp;vitro</em> data suggests that the majority of NS5A&nbsp;RAVs that confer resistance to ledipasvir and daclatasvir remained susceptible to velpatasvir.&nbsp; Velpatasvir was fully active against the sofosbuvir resistance-associated substitution S282T in NS5B while all velpatasvir resistance-associated substitutions in NS5A were fully susceptible to sofosbuvir.&nbsp; Both sofosbuvir and velpatasvir were fully active against substitutions associated with resistance to other classes of direct acting antivirals with different mechanisms of actions, such as NS5B non‑nucleoside inhibitors and NS3 protease inhibitors.&nbsp; The efficacy of Epclusa has not been assessed in patients who have previously failed treatment with other regimens that include an NS5A inhibitor.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Adults</u></em></p><p>The efficacy of Epclusa was evaluated in three Phase&nbsp;3 studies in patients with genotype&nbsp;1 to 6 HCV infection with or without compensated cirrhosis, one Phase&nbsp;3 study in patients with genotype&nbsp;1 to 6 HCV infection with decompensated cirrhosis, one Phase&nbsp;3 study in HCV/HIV-1 co-infected patients with genotype&nbsp;1 to 6 HCV infection and one Phase 2 trial in patients with HCV infection and ESRD requiring dialysis, as summarised in Table&nbsp;10.</p><p>&nbsp;</p><p><strong>Table&nbsp;10: Studies conducted with Epclusa in adult patients with genotype&nbsp;1, 2, 3, 4, 5 or 6 HCV infection</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Population</strong></p></td><td style="vertical-align:top"><p><strong>Study arms</strong></p><p><strong>(Number of patients treated)</strong></p></td></tr></thead><tbody><tr><td><p>ASTRAL‑1</p></td><td><p>Genotype&nbsp;1, 2, 4, 5 and 6</p><p>TN and TE, without cirrhosis or with compensated cirrhosis</p></td><td><p>Epclusa 12&nbsp;weeks (624)</p><p>Placebo 12&nbsp;weeks (116)</p></td></tr><tr><td><p>ASTRAL‑2</p></td><td><p>Genotype&nbsp;2</p><p>TN and TE, without cirrhosis or with compensated cirrhosis</p></td><td><p>Epclusa 12&nbsp;weeks (134)</p><p>SOF+RBV 12&nbsp;weeks (132)</p></td></tr><tr><td><p>ASTRAL‑3</p></td><td><p>Genotype&nbsp;3</p><p>TN and TE, without cirrhosis or with compensated cirrhosis</p></td><td><p>Epclusa 12&nbsp;weeks (277)</p><p>SOF+RBV 24&nbsp;weeks (275)</p></td></tr><tr><td><p>ASTRAL‑4</p></td><td><p>Genotype&nbsp;1, 2, 3, 4, 5 and 6</p><p>TN and TE, with CPT Class&nbsp;B decompensated cirrhosis</p></td><td><p>Epclusa 12&nbsp;weeks (90)</p><p>Epclusa + RBV 12&nbsp;weeks (87)</p><p>Epclusa 24&nbsp;weeks (90)</p></td></tr><tr><td><p>ASTRAL‑5</p></td><td><p>Genotype&nbsp;1, 2, 3, 4, 5 and 6</p><p>TN and TE, without cirrhosis or with compensated cirrhosis, with HCV/HIV-1 co-infection</p></td><td><p>Epclusa 12&nbsp;weeks (106)</p></td></tr><tr><td><p>GS‑US‑342‑4062</p></td><td><p>TN and TE with or without cirrhosis, with ESRD requiring dialysis</p></td><td><p>Epclusa 12&nbsp;weeks (59)</p><p>&nbsp;</p></td></tr></tbody></table><p>TN&nbsp;=&nbsp;treatment-na&iuml;ve patients; TE&nbsp;=&nbsp;treatment-experienced patients (including those who have failed a peginterferon alfa + ribavirin based regimen with or without an HCV protease inhibitor)</p><p>&nbsp;</p><p>The ribavirin dose was weight-based (1,000&nbsp;mg daily administered in two divided doses for patients &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for those &ge;&nbsp;75&nbsp;kg) and administered in two divided doses when used in combination with sofosbuvir in the ASTRAL‑2 and ASTRAL‑3 studies or in combination with Epclusa in the ASTRAL‑4 study. &nbsp;Ribavirin dose adjustments were performed according to the ribavirin prescribing information.&nbsp; Serum HCV&nbsp;RNA values were measured during the clinical studies using the COBAS AmpliPrep/COBAS Taqman HCV test (version&nbsp;2.0) with a lower limit of quantification (LLOQ) of 15&nbsp;IU/mL. &nbsp;Sustained virologic response (SVR12), defined as HCV&nbsp;RNA less than LLOQ at 12&nbsp;weeks after the cessation of treatment, was the primary endpoint to determine the HCV cure rate.</p><p>&nbsp;</p><p><em>Clinical studies in patients without cirrhosis and patients with compensated cirrhosis</em></p><p><em>Genotype&nbsp;1, 2, 4, 5 and 6 HCV‑infected adults <strong>&ndash;</strong> ASTRAL‑1 (study&nbsp;1138)</em></p><p>ASTRAL‑1 was a randomised, double-blind, placebo-controlled study that evaluated 12&nbsp;weeks of treatment with Epclusa compared with 12&nbsp;weeks of placebo in patients with genotype&nbsp;1, 2, 4, 5, or 6 HCV infection.&nbsp; Patients with genotype&nbsp;1, 2, 4 or 6 HCV infection were randomised in a 5:1 ratio to treatment with Epclusa for 12&nbsp;weeks or placebo for 12&nbsp;weeks. &nbsp;Patients with genotype&nbsp;5 HCV infection were enrolled to the Epclusa group.&nbsp; Randomisation was stratified by HCV genotype (1, 2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.</p><p>Demographics and baseline characteristics were balanced between the Epclusa and placebo group. &nbsp;Of the 740&nbsp;treated patients, the median age was 56&nbsp;years (range: 18 to 82); 60% of the patients were male; 79% were White, 9% were Black; 21% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>; the proportions of patients with genotype&nbsp;1, 2, 4, 5, or 6 HCV infection were 53%, 17%, 19%, 5% and 7%, respectively; 69% had non‑CC IL28B alleles (CT or TT); 74% had baseline HCV&nbsp;RNA levels of at least 800,000&nbsp;IU/mL; 19% had compensated cirrhosis; and 32% were treatment-experienced.</p><p>&nbsp;</p><p>Table&nbsp;11 presents the SVR12 for the ASTRAL‑1 study by HCV genotypes. &nbsp;No patients in the placebo group achieved SVR12.</p><p><strong>Table&nbsp;11: SVR12 in study ASTRAL‑1 by HCV genotype</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><thead><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="8" style="vertical-align:top"><p><strong>Epclusa 12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;624)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(all GTs)</strong></p><p><strong>(n&nbsp;=&nbsp;624)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>GT‑1</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑2</strong></p><p><strong>(n&nbsp;=&nbsp;104)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑4</strong></p><p><strong>(n&nbsp;=&nbsp;116)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑5</strong></p><p><strong>(n&nbsp;=&nbsp;35)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑6</strong></p><p><strong>(n&nbsp;=&nbsp;41)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>GT‑1a</strong></p><p><strong>(n&nbsp;=&nbsp;210)</strong></p></td><td style="vertical-align:top"><p><strong>GT‑1b</strong></p><p><strong>(n&nbsp;=&nbsp;118)</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(n&nbsp;=&nbsp;328)</strong></p></td></tr></thead><tbody><tr><td><p>SVR12</p></td><td><p>99%</p><p>(618/624)</p></td><td><p>98%</p><p>(206/210)</p></td><td><p>99%</p><p>(117/118)</p></td><td><p>98%</p><p>(323/328)</p></td><td><p>100%</p><p>(104/104)</p></td><td><p>100%</p><p>(116/116)</p></td><td><p>97%</p><p>(34/35)</p></td><td><p>100%</p><p>(41/41)</p></td></tr><tr><td colspan="9"><p>Outcome for patients without SVR12</p></td></tr><tr><td><p>On-treatment virologic failure</p></td><td><p>0/624</p></td><td><p>0/210</p></td><td><p>0/118</p></td><td><p>0/328</p></td><td><p>0/104</p></td><td><p>0/116</p></td><td><p>0/35</p></td><td><p>0/41</p></td></tr><tr><td><p>Relapse<sup>a</sup></p></td><td><p>&lt;&nbsp;1%</p><p>(2/623)</p></td><td><p>&lt;&nbsp;1%</p><p>(1/209)</p></td><td><p>1%</p><p>(1/118)</p></td><td><p>1%</p><p>(2/327)</p></td><td><p>0/104</p></td><td><p>0/116</p></td><td><p>0/35</p></td><td><p>0/41</p></td></tr><tr><td><p>Other<sup>b</sup></p></td><td><p>1%</p><p>(4/624)</p></td><td><p>1%</p><p>(3/210)</p></td><td><p>0/118</p></td><td><p>1%</p><p>(3/328)</p></td><td><p>0/104</p></td><td><p>0/116</p></td><td><p>3%</p><p>(1/35)</p></td><td><p>0/41</p></td></tr></tbody></table><p>GT&nbsp;=&nbsp;genotype</p><p>a&nbsp; &nbsp;The denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ at their last on-treatment assessment.</p><p>b&nbsp; &nbsp;Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.</p><p><em>&nbsp;</em></p><p><em>Genotype&nbsp;2 HCV‑infected adults <strong>&ndash;</strong> ASTRAL‑2 (study&nbsp;1139)</em></p><p>ASTRAL‑2 was a randomised, open-label study that evaluated 12&nbsp;weeks of treatment with Epclusa compared with 12&nbsp;weeks of treatment with SOF+RBV in patients with genotype&nbsp;2 HCV infection.&nbsp; Patients were randomised in a 1:1 ratio to treatment with Epclusa for 12&nbsp;weeks or SOF+RBV for 12&nbsp;weeks.&nbsp; Randomisation was stratified by the presence or absence of cirrhosis and prior treatment experience (treatment‑na&iuml;ve <em>versus</em> treatment‑experienced).</p><p>Demographics and baseline characteristics were balanced across the two treatment groups.&nbsp; Of the 266 treated patients, the median age was 58&nbsp;years (range: 23 to 81); 59% of the patients were male; 88% were White, 7% were Black; 33% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>; 62% had non‑CC IL28B alleles (CT or TT); 80% had baseline HCV&nbsp;RNA levels of at least 800,000&nbsp;IU/mL; 14% had compensated cirrhosis and 15% were treatment-experienced.</p><p>&nbsp;</p><p>Table&nbsp;12 presents the SVR12 for the ASTRAL‑2 study.</p><p><strong>Table&nbsp;12: SVR12 in study ASTRAL‑2 (HCV genotype&nbsp;2)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Epclusa 12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;134)</strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV</strong></p><p><strong>12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;132)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>SVR12</p></td><td style="vertical-align:top"><p>99% (133/134)</p></td><td style="vertical-align:top"><p>94% (124/132)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Outcome for patients without SVR12</p></td></tr><tr><td style="vertical-align:top"><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>0/134</p></td><td style="vertical-align:top"><p>0/132</p></td></tr><tr><td style="vertical-align:top"><p>Relapse<sup>a</sup></p></td><td style="vertical-align:top"><p>0/133</p></td><td style="vertical-align:top"><p>5% (6/132)</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>b</sup></p></td><td style="vertical-align:top"><p>1% (1/134)</p></td><td style="vertical-align:top"><p>2% (2/132)</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ at their last on-treatment assessment.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.</p><p>&nbsp;</p><p>Treatment with Epclusa for 12&nbsp;weeks demonstrated the statistical superiority (p&nbsp;=&nbsp;0.018) over treatment with SOF+RBV for 12&nbsp;weeks (treatment difference +5.2%; 95% confidence interval: +0.2% to +10.3%).</p><p><em>Genotype&nbsp;3 HCV‑infected adults <strong>&ndash;</strong> ASTRAL‑3 (study&nbsp;1140)</em></p><p>ASTRAL‑3 was a randomised, open-label study that evaluated 12&nbsp;weeks of treatment with Epclusa compared with 24&nbsp;weeks of treatment with SOF+RBV in patients with genotype&nbsp;3 HCV infection.&nbsp; Patients were randomised in a 1:1 ratio to treatment with Epclusa for 12&nbsp;weeks or SOF+RBV for 24&nbsp;weeks.&nbsp; Randomisation was stratified by the presence or absence of cirrhosis and prior treatment experience (treatment‑na&iuml;ve <em>versus</em> treatment‑experienced).</p><p>Demographics and baseline characteristics were balanced across the two treatment groups.&nbsp; Of the 552 treated patients, the median age was 52&nbsp;years (range: 19 to 76); 62% of the patients were male; 89% were White, 9% were Asian; 1% were Black; 20% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>; 61% had non‑CC IL28B alleles (CT or TT); 70% had baseline HCV&nbsp;RNA levels of at least 800,000&nbsp;IU/mL, 30% had compensated cirrhosis and 26% were treatment-experienced.</p><p>&nbsp;</p><p>Table&nbsp;13 presents the SVR12 for the ASTRAL‑3 study.</p><p><strong>Table&nbsp;13: SVR12 in study ASTRAL‑3 (HCV genotype&nbsp;3)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Epclusa 12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;277)</strong></p></td><td style="vertical-align:top"><p><strong>SOF+RBV</strong></p><p><strong>24&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;275)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>SVR12</p></td><td style="vertical-align:top"><p>95% (264/277)</p></td><td style="vertical-align:top"><p>80% (221/275)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Outcome for patients without SVR12</p></td></tr><tr><td style="vertical-align:top"><p>On-treatment virologic failure</p></td><td style="vertical-align:top"><p>0/277</p></td><td style="vertical-align:top"><p>&lt;&nbsp;1% (1/275)</p></td></tr><tr><td style="vertical-align:top"><p>Relapse<sup>a</sup></p></td><td style="vertical-align:top"><p>4% (11/276)</p></td><td style="vertical-align:top"><p>14% (38/272)</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>b</sup></p></td><td style="vertical-align:top"><p>1% (2/277)</p></td><td style="vertical-align:top"><p>5% (15/275)</p></td></tr></tbody></table><p>a&nbsp; &nbsp;The denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ at their last on-treatment assessment.</p><p>b&nbsp; &nbsp;Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.</p><p>&nbsp;</p><p>Treatment with Epclusa for 12&nbsp;weeks demonstrated the statistical superiority (p&nbsp;&lt;&nbsp;0.001) compared to treatment with SOF+RBV for 24&nbsp;weeks (treatment difference +14.8%; 95% confidence interval: +9.6% to +20.0%).</p><p>SVR12 for selected subgroups are presented in Table&nbsp;14.</p><p><strong>Table&nbsp;14: SVR12 for selected subgroups in study ASTRAL‑3 (HCV genotype&nbsp;3)</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Epclusa</strong></p><p><strong>12&nbsp;weeks</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>SOF+RBV</strong></p><p><strong>24&nbsp;weeks<sup>a</sup></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>SVR12</p></td><td style="vertical-align:top"><p>Treatment-na&iuml;ve</p><p>(n&nbsp;=&nbsp;206)</p></td><td style="vertical-align:top"><p>Treatment-experienced</p><p>(n&nbsp;=&nbsp;71)</p></td><td style="vertical-align:top"><p>Treatment-na&iuml;ve</p><p>(n&nbsp;=&nbsp;201)</p></td><td style="vertical-align:top"><p>Treatment-experienced</p><p>(n&nbsp;=&nbsp;69)</p></td></tr><tr><td style="vertical-align:top"><p>Without cirrhosis</p></td><td style="vertical-align:top"><p>98% (160/163)</p></td><td style="vertical-align:top"><p>91% (31/34)</p></td><td style="vertical-align:top"><p>90% (141/156)</p></td><td style="vertical-align:top"><p>71% (22/31)</p></td></tr><tr><td style="vertical-align:top"><p>With cirrhosis</p></td><td style="vertical-align:top"><p>93% (40/43)</p></td><td style="vertical-align:top"><p>89% (33/37)</p></td><td style="vertical-align:top"><p>73% (33/45)</p></td><td style="vertical-align:top"><p>58% (22/38)</p></td></tr></tbody></table><p>a&nbsp; &nbsp;Five patients with missing cirrhosis status in the SOF+RBV 24&nbsp;week group were excluded from this subgroup analysis.</p><p>&nbsp;</p><p><em>Clinical studies in patients with decompensated cirrhosis <strong>&ndash;</strong> ASTRAL‑4 (study&nbsp;1137)</em></p><p>ASTRAL‑4 was a randomised, open-label study in patients with genotype&nbsp;1, 2, 3, 4, 5 or 6 HCV infection and CPT Class&nbsp;B cirrhosis.&nbsp; Patients were randomised in a 1:1:1 ratio to treatment with Epclusa for 12&nbsp;weeks, Epclusa + RBV for 12&nbsp;weeks or Epclusa for 24&nbsp;weeks.&nbsp; Randomisation was stratified by HCV genotype (1, 2, 3, 4, 5, 6 and indeterminate).</p><p>Demographics and baseline characteristics were balanced across the treatment groups.&nbsp; Of the 267 treated patients, the median age was 59&nbsp;years (range: 40 to 73); 70% of the patients were male; 90% were White, 6% were Black; 42% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>.&nbsp; The proportions of patients with genotype&nbsp;1, 2, 3, 4 or 6 HCV were 78%, 4%, 15%, 3%, and &lt;&nbsp;1% (1&nbsp;patient), respectively.&nbsp; No patients with genotype&nbsp;5 HCV infection were enrolled.&nbsp; 76% of the patients had non‑CC IL28B alleles (CT or TT); 56% had baseline HCV&nbsp;RNA levels of at least 800,000&nbsp;IU/mL, 55% were treatment-experienced; 90% and 95% of patients had CPT Class&nbsp;B cirrhosis and Model for End Stage Liver Disease (MELD) score &le;&nbsp;15 at baseline, respectively.</p><p>&nbsp;</p><p>Table&nbsp;15 presents the SVR12 for the ASTRAL‑4 study by HCV genotype.</p><p><strong>Table&nbsp;15: SVR12 in study ASTRAL‑4 by HCV genotype</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Epclusa</strong></p><p><strong>12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;90)</strong></p></td><td style="vertical-align:top"><p><strong>Epclusa + RBV</strong></p><p><strong>12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;87)</strong></p></td><td style="vertical-align:top"><p><strong>Epclusa</strong></p><p><strong>24&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;90)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Overall SVR12</strong></p></td><td style="vertical-align:top"><p>83% (75/90)</p></td><td style="vertical-align:top"><p>94% (82/87)</p></td><td style="vertical-align:top"><p>86% (77/90)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;1</strong></p></td><td style="vertical-align:top"><p>88% (60/68)</p></td><td style="vertical-align:top"><p>96% (65/68)</p></td><td style="vertical-align:top"><p>92% (65/71)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1a</strong></p></td><td style="vertical-align:top"><p>88% (44/50)</p></td><td style="vertical-align:top"><p>94% (51/54)</p></td><td style="vertical-align:top"><p>93% (51/55)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1b</strong></p></td><td style="vertical-align:top"><p>89% (16/18)</p></td><td style="vertical-align:top"><p>100% (14/14)</p></td><td style="vertical-align:top"><p>88% (14/16)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;3</strong></p></td><td style="vertical-align:top"><p>50% (7/14)</p></td><td style="vertical-align:top"><p>85% (11/13)</p></td><td style="vertical-align:top"><p>50% (6/12)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;2, 4 and 6</strong></p></td><td style="vertical-align:top"><p>100% (8/8)<sup>a</sup></p></td><td style="vertical-align:top"><p>100% (6/6)<sup>b</sup></p></td><td style="vertical-align:top"><p>86% (6/7)<sup>c</sup></p></td></tr></tbody></table><p>a&nbsp; n&nbsp;=&nbsp;4 for genotype&nbsp;2 and n&nbsp;=&nbsp;4 for genotype&nbsp;4</p><p>b&nbsp; n&nbsp;=&nbsp;4 for genotype&nbsp;2 and n&nbsp;=&nbsp;2 for genotype&nbsp;4</p><p>c&nbsp; n&nbsp;=&nbsp;4 for genotype&nbsp;2, n&nbsp;=&nbsp;2 for genotype&nbsp;4 and n&nbsp;=&nbsp;1 for genotype&nbsp;6.</p><p><strong>&nbsp;</strong></p><p>Table&nbsp;16 presents the virologic outcome for patients with genotype&nbsp;1 or 3 HCV infection in the ASTRAL‑4 study.</p><p>No patients with genotype&nbsp;2, 4 or 6 HCV infection experienced virologic failure.</p><p><strong>Table&nbsp;16: Virologic outcome for patients with genotype&nbsp;1 and 3 HCV infection in study ASTRAL‑4</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Epclusa </strong><strong>12&nbsp;weeks</strong></p></td><td style="vertical-align:top"><p><strong>Epclusa </strong><strong>+ RBV 12&nbsp;weeks</strong></p></td><td style="vertical-align:top"><p><strong>Epclusa </strong><strong>24&nbsp;weeks</strong></p></td></tr></thead><tbody><tr><td colspan="4" style="vertical-align:top"><p>Virologic failure (relapse and on-treatment failure)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;1<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>7% (5/68)</p></td><td style="vertical-align:top"><p>1% (1/68)</p></td><td style="vertical-align:top"><p>4% (3/71)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1a</strong></p></td><td style="vertical-align:top"><p>6% (3/50)</p></td><td style="vertical-align:top"><p>2% (1/54)</p></td><td style="vertical-align:top"><p>4% (2/55)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1b</strong></p></td><td style="vertical-align:top"><p>11% (2/18)</p></td><td style="vertical-align:top"><p>0% (0/14)</p></td><td style="vertical-align:top"><p>&nbsp;6% (1/16)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genotype&nbsp;3</strong></p></td><td style="vertical-align:top"><p>43% (6/14)</p></td><td style="vertical-align:top"><p>15% (2<sup>b</sup>/13)</p></td><td style="vertical-align:top"><p>42% (5<sup>c</sup>/12)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Other<sup>d</sup></strong></p></td><td style="vertical-align:top"><p>5% (4/82)</p></td><td style="vertical-align:top"><p>2% (2/81)</p></td><td style="vertical-align:top"><p>5% (4/83)</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No patients with genotype&nbsp;1 HCV had on-treatment virologic failure.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One patient had on-treatment virologic failure; pharmacokinetic data from this patient was consistent with non-adherence to treatment.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One patient had on-treatment virologic failure.</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.</p><p>&nbsp;</p><p>Changes in the parameters found in the CPT score system in patients achieving SVR12 in ASTRAL-4 (all 3 regimens) are shown in Table&nbsp;17.</p><p><strong>Table&nbsp;17: Changes in CPT score parameters from baseline to week 12 and 24 post‑treatment in patients achieving SVR12, ASTRAL-4</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:641px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Albumin</strong></p></td><td style="vertical-align:top"><p><strong>B</strong><strong>ili</strong><strong>rubin</strong></p></td><td style="vertical-align:top"><p><strong>I</strong><strong>NR</strong></p></td><td style="vertical-align:top"><p><strong>Ascites</strong></p></td><td style="vertical-align:top"><p><strong>En</strong><strong>cephalopathy</strong></p></td></tr><tr><td colspan="6"><p><strong>P</strong><strong>o</strong><strong>st‑t</strong><strong>reatment Week 12 (N = 236), % (n/N) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased score (Improvement)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>34.5% (79/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17.9% (41/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.2% (5/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.9% (18/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.2% (12/229)</p></td></tr><tr><td style="vertical-align:top"><p>No change</p></td><td style="vertical-align:top"><p>60.3% (138/229)</p></td><td style="vertical-align:top"><p>76.4% (175/229)</p></td><td style="vertical-align:top"><p>96.5% (221/229)</p></td><td style="vertical-align:top"><p>89.1% (204/229)</p></td><td style="vertical-align:top"><p>91.3% (209/229)</p></td></tr><tr><td style="vertical-align:top"><p>Increased score (Worsening)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.2% (12/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.7% (13/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.3% (3/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.1% (7/229)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.5% (8/229)</p></td></tr><tr><td style="vertical-align:top"><p>No assessment</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>P</strong><strong>o</strong><strong>st‑t</strong><strong>reatment Week 24 (N = 236), % (n/N)</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Decreased score (Improvement)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39.4% (84/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16.4% (35/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.3% (5/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15.0% (32/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.4% (20/213)</p></td></tr><tr><td style="vertical-align:top"><p>No change</p></td><td style="vertical-align:top"><p>54.0% (115/213)</p></td><td style="vertical-align:top"><p>80.8% (172/213)</p></td><td style="vertical-align:top"><p>94.8% (202/213)</p></td><td style="vertical-align:top"><p>81.2% (173/213)</p></td><td style="vertical-align:top"><p>88.3% (188/213)</p></td></tr><tr><td style="vertical-align:top"><p>Increased score (Worsening)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>6.6% (14/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.8% (6/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.8% (6/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.8% (8/213)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.3% (5/213)</p></td></tr><tr><td style="vertical-align:top"><p>No assessment</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>23</p></td></tr></tbody></table><p>Note:&nbsp;&nbsp;&nbsp; Baseline frequency of ascites was: 20% none, 77% mild/moderate, 3% severe</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline frequency of encephalopathy was: 38% none, 62 % grade 1-2.</p><p>&nbsp;</p><p><em>Clinical studies in patients with HCV/HIV-1 Co-infection <strong>&ndash;</strong> ASTRAL‑5 (study&nbsp;1202)</em></p><p>ASTRAL‑5 evaluated 12&nbsp;weeks of treatment with Epclusa in patients with genotype 1, 2, 3, or 4 HCV infection who were co-infected with HIV-1 (HCV genotype 5 and 6 allowed, but no such patients were included). &nbsp;Patients were on a stable HIV-1 antiretroviral therapy that included emtricitabine/tenofovir disoproxil fumarate or abacavir/lamivudine administered with a ritonavir boosted protease inhibitor (atazanavir, darunavir, or lopinavir), rilpivirine, raltegravir or emtricitabine/tenofovir disoproxil fumarate /elvitegravir/cobicistat.</p><p>Of the 106 treated patients, the median age was 57&nbsp;years (range: 25 to 72); 86% of the patients were male; 51% were white; 45% were black; 22% had a baseline body mass index &ge; 30&nbsp;kg/m<sup>2</sup>; 19 patients (18%) had compensated cirrhosis; and 29% were treatment experienced.&nbsp; The overall mean CD4+ count was 598&nbsp;cells/&micro;L (range: 183&minus;1513 cells/&micro;L).</p><p>&nbsp;</p><p>Table&nbsp;18 presents the SVR12 for the ASTRAL‑5 study by HCV genotype.</p><p><strong>Table&nbsp;18: SVR12 in study ASTRAL‑5 by HCV genotype</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><thead><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="7" style="vertical-align:top"><p><strong>Epclusa 12&nbsp;weeks</strong></p><p><strong>(n&nbsp;=&nbsp;106)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(all GTs)</strong></p><p><strong>(n&nbsp;=&nbsp;106)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>GT‑1</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑2</strong></p><p><strong>(n&nbsp;=&nbsp;11)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑3</strong></p><p><strong>(n&nbsp;=&nbsp;12)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>GT‑4</strong></p><p><strong>(n&nbsp;=&nbsp;5)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>GT‑1a</strong></p><p><strong>(n&nbsp;=&nbsp;66)</strong></p></td><td style="vertical-align:top"><p><strong>GT‑1b</strong></p><p><strong>(n&nbsp;=&nbsp;12)</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(n&nbsp;=&nbsp;78)</strong></p></td></tr></thead><tbody><tr><td><p>SVR12</p></td><td><p>95%</p><p>(101/106)</p></td><td><p>95%</p><p>(63/66)</p></td><td><p>92%</p><p>(11/12)</p></td><td><p>95%</p><p>(74/78)</p></td><td><p>100%</p><p>(11/11)</p></td><td><p>92%</p><p>(11/12)</p></td><td><p>100%</p><p>(5/5)</p></td></tr><tr><td colspan="8"><p>Outcome for patients without SVR</p></td></tr><tr><td><p>On-treatment virologic failure</p></td><td><p>0/106</p></td><td><p>0/66</p></td><td><p>0/12</p></td><td><p>0/78</p></td><td><p>0/11</p></td><td><p>0/12</p></td><td><p>0/5</p></td></tr><tr><td><p>Relapse<sup>a</sup></p></td><td><p>2%</p><p>(2/103)</p></td><td><p>3%</p><p>(2/65)</p></td><td><p>0/11</p></td><td><p>3%</p><p>(2/76)</p></td><td><p>0/11</p></td><td><p>0/11</p></td><td><p>0/5</p></td></tr><tr><td><p>Other<sup>b</sup></p></td><td><p>3%</p><p>(3/106)</p></td><td><p>2%</p><p>(1/66)</p></td><td><p>8%</p><p>(1/12)</p></td><td><p>3%</p><p>(2/78)</p></td><td><p>0/11</p></td><td><p>8%</p><p>(1/12)</p></td><td><p>0/5</p></td></tr></tbody></table><p>GT&nbsp;=&nbsp;genotype</p><p>a&nbsp; The denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ at their last on-treatment assessment.</p><p>b&nbsp; Other includes patients who did not achieve SVR12 and did not meet virologic failure criteria.</p><p>SVR12 was achieved by 19/19 patients with cirrhosis. No patient had HIV-1 rebound during the study, and CD4+ counts were stable during treatment.</p><p><em>Clinical studies in patients with Renal Impairment &ndash; study&nbsp;4062</em></p><p>Study&nbsp;4062 was an open-label clinical trial that evaluated 12 weeks of treatment with Epclusa in 59 HCV-infected patients with ESRD requiring dialysis. &nbsp;The proportions of patients with genotype 1, 2, 3, 4, 6 or indeterminate HCV infection were 42%, 12%, 27%, 7%, 3%, and 9%, respectively. &nbsp;At baseline, 29% of patients had cirrhosis, 22% were treatment experienced, 32% had received a kidney transplant, 92% were on haemodialysis, and 8% were on peritoneal dialysis; mean duration on dialysis was 7.3 years (range: 0 to 40 years). &nbsp;The overall SVR rate was 95% (56/59); of the three patients that did not achieve SVR12, one had completed Epclusa treatment and relapsed and two did not meet virologic failure criteria.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The efficacy of 12 weeks of treatment with sofosbuvir/velpatasvir in HCV-infected paediatric patients aged 12 years and older with genotype 1,2,3,4 or 6 HCV infection was evaluated in a Phase 2, open-label clinical study in 102 patients with HCV infection.</p><p>A total of 80 patients (78%) were treatment-na&iuml;ve and 22 patients (22%) were treatment-experienced.&nbsp; The median age was 15 years (range: 12 to 17); 51% of the patients were female; 73% were White, 9% were Black, and 11% were Asian; 14% were Hispanic/Latino; mean body mass index was 22.7 kg/m<sup>2</sup> (range: 12.9 to 48.9 kg/m<sup>2</sup>); mean weight was 61&nbsp;kg (range&nbsp;22&nbsp;to&nbsp;147&nbsp;kg); 58% had baseline HCV RNA levels greater than or equal to 800,000&nbsp;IU/mL; the proportions of subjects with genotype 1, 2, 3, 4, or 6 HCV infection were 74%, 6%, 12%, 2%, and 6%, respectively; no patients had known cirrhosis. &nbsp;The majority of patients (89%) had been infected through vertical transmission.</p><p>The SVR rate was 95% overall (97/102), 93% (71/76) in patients with genotype 1 HCV infection, and 100% in patients with genotype 2 (6/6), genotype 3 (12/12), genotype 4 (2/2), and genotype 6 (6/6) HCV infection.&nbsp; One patient who discontinued treatment early relapsed; the other four patients who did not achieve SVR12 did not meet virologic failure criteria (e.g., lost to follow-up).</p><p><em>Elderly</em></p><p>Clinical studies of Epclusa included 156&nbsp;patients aged&nbsp;65 and over (12% of total number of patients in the Phase&nbsp;3 clinical studies).&nbsp; The response rates observed for patients &ge;&nbsp;65&nbsp;years of age were similar to that of patients &lt;&nbsp;65&nbsp;years of age, across treatment groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The pharmacokinetic properties of sofosbuvir, GS‑331007 and velpatasvir have been evaluated in healthy adult subjects and in patients with chronic hepatitis&nbsp;C.&nbsp; Following oral administration of Epclusa, sofosbuvir was absorbed quickly and the peak median plasma concentration was observed 1&nbsp;hour post‑dose.&nbsp; Median peak plasma concentration of GS‑331007 was observed 3&nbsp;hours post‑dose.&nbsp; Velpatasvir median peak concentrations were observed at 3&nbsp;hours post‑dose.</p><p>Based on the population pharmacokinetic analysis in HCV‑infected patients, mean steady‑state AUC<sub>0‑24</sub> for sofosbuvir (n&nbsp;=&nbsp;982), GS‑331007 (n&nbsp;=&nbsp;1,428) and velpatasvir (n&nbsp;=&nbsp;1,425) were 1,260, 13,970 and 2,970&nbsp;ng&bull;h/mL, respectively.&nbsp; Steady-state C<sub>max</sub> for sofosbuvir, GS‑331007 and velpatasvir were 566, 868 and 259&nbsp;ng/mL, respectively.&nbsp; Sofosbuvir and GS‑331007 AUC<sub>0‑24</sub> and C<sub>max</sub> were similar in healthy adult subjects and patients with HCV infection.&nbsp; Relative to healthy subjects (n&nbsp;=&nbsp;331), velpatasvir AUC<sub>0‑24</sub> and C<sub>max</sub> were 37% lower and 41% lower, respectively in HCV‑infected patients.</p><p><em>Effects of food</em></p><p>Relative to fasting conditions, the administration of a single dose of Epclusa with a moderate fat (~600&nbsp;kcal, 30% fat) or high fat (~800&nbsp;kcal, 50% fat) meal resulted in a 34% and 21% increase in velpatasvir AUC<sub>0‑inf</sub>, respectively, and a 31% and 5% increase in velpatasvir C<sub>max</sub>, respectively.&nbsp; The moderate or high fat meal increased sofosbuvir AUC<sub>0‑inf</sub> by 60% and 78%, respectively, but did not substantially affect the sofosbuvir C<sub>max</sub>. &nbsp;The moderate or high fat meal did not alter GS‑331007 AUC<sub>0‑inf</sub>, but resulted in a 25% and 37% decrease in its C<sub>max</sub>, respectively. &nbsp;The response rates in Phase&nbsp;3 studies were similar in HCV‑infected patients who received Epclusa with food or without food. &nbsp;Epclusa can be administered without regard to food.</p><p><u>Distribution</u></p><p>Sofosbuvir is approximately 61‑65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1&nbsp;&micro;g/mL to 20&nbsp;&micro;g/mL.&nbsp; Protein binding of GS‑331007 was minimal in human plasma.&nbsp; After a single 400&nbsp;mg dose of [<sup>14</sup>C]‑sofosbuvir in healthy subjects, the blood to plasma ratio of [<sup>14</sup>C]‑radioactivity was approximately 0.7.</p><p>Velpatasvir is &gt;&nbsp;99.5% bound to human plasma proteins and binding is independent of drug concentration over the range of 0.09&nbsp;&micro;g/mL to 1.8&nbsp;&micro;g/mL. &nbsp;After a single 100&nbsp;mg dose of [<sup>14</sup>C]‑velpatasvir in healthy subjects, the blood to plasma ratio of [<sup>14</sup>C]‑radioactivity ranged between 0.52 and 0.67.</p><p><u>Biotransformation</u></p><p>Sofosbuvir is extensively metabolised in the liver to form the pharmacologically active nucleoside analog triphosphate GS‑461203. &nbsp;The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalysed by human cathepsin A (CatA) or carboxylesterase&nbsp;1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway.&nbsp; Dephosphorylation results in the formation of nucleoside metabolite GS‑331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity <em>in&nbsp;vitro.</em> &nbsp;Sofosbuvir and GS‑331007 are not substrates or inhibitors of UGT1A1 or CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzymes.&nbsp; After a single 400&nbsp;mg oral dose of [<sup>14</sup>C]-sofosbuvir, GS‑331007 accounted for approximately &gt;&nbsp;90% of total systemic exposure.</p><p>Velpatasvir is a substrate of CYP2B6, CYP2C8, and CYP3A4 with slow turnover. &nbsp;Following a single dose of 100&nbsp;mg [<sup>14</sup>C]‑velpatasvir, the majority (&gt;&nbsp;98%) of radioactivity in plasma was parent drug.&nbsp; The monohydroxylated and desmethylated velpatasvir were the metabolites identified in human plasma.&nbsp; Unchanged velpatasvir is the major species present in faeces.</p><p><u>Elimination</u></p><p>Following a single 400&nbsp;mg oral dose of [<sup>14</sup>C]‑sofosbuvir, mean total recovery of the [<sup>14</sup>C]‑radioactivity was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and expired air, respectively.&nbsp; The majority of the sofosbuvir dose recovered in urine was GS‑331007 (78%) while 3.5% was recovered as sofosbuvir.&nbsp; These data indicate that renal clearance is the major elimination pathway for GS‑331007.&nbsp; The median terminal half‑lives of sofosbuvir and GS‑331007 following administration of Epclusa were 0.5 and 25&nbsp;hours, respectively.</p><p>Following a single 100&nbsp;mg oral dose of [<sup>14</sup>C]‑velpatasvir, mean total recovery of the [<sup>14</sup>C]‑radioactivity was 95%, consisting of approximately 94% and 0.4% recovered from the faeces and urine, respectively.&nbsp; Unchanged velpatasvir was the major species in faeces accounting for a mean of 77% of the administered dose, followed by monohydroxylated velpatasvir (5.9%) and desmethylated velpatasvir (3.0%).&nbsp; These data indicate that biliary excretion of parent drug was a major route of elimination for velpatasvir. &nbsp;The median terminal half-life of velpatasvir following administration of Epclusa was approximately 15&nbsp;hours.</p><p><u>Linearity/non-linearity </u></p><p>Velpatasvir AUC increases in a nearly dose proportional manner over the dose range of 25&nbsp;mg to 150&nbsp;mg.&nbsp; Sofosbuvir and GS‑331007 AUCs are near dose‑proportional over the dose range of 200&nbsp;mg to 1,200&nbsp;mg.</p><p><em><u>In&nbsp;vitro</u></em><u> potential for sofosbuvir/velpatasvir drug-drug interactions</u></p><p>Sofosbuvir and velpatasvir are substrates of drug transporters P‑gp and BCRP while GS‑331007 is not.&nbsp; Velpatasvir is also a substrate of OATP1B.&nbsp; <em>In&nbsp;vitro,</em> slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed.</p><p>Velpatasvir is an inhibitor of drug transporter P‑gp, BCRP, OATP1B1 and OATP1B3 and its involvement in drug interactions with these transporters is primarily limited to the process of absorption.&nbsp; At clinically relevant plasma concentration, velpatasvir is not an inhibitor of hepatic transporters bile salt export pump (BSEP), sodium taurocholate cotransporter protein (NTCP), OATP2B1, OATP1A2 or organic cation transporter (OCT)&nbsp;1, renal transporters OCT2, OAT1, OAT3, multidrug resistance-associated protein 2 (MRP2) or multidrug and toxin extrusion protein (MATE)&nbsp;1, or CYP or uridine glucuronosyltransferase (UGT)&nbsp;1A1 enzymes.</p><p>Sofosbuvir and GS‑331007 are not inhibitors of drug transporters P‑-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3 and OCT1. &nbsp;GS‑331007 is not an inhibitor of OAT1, OCT2, and MATE1.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Race and gender</em></p><p>No clinically relevant pharmacokinetic differences due to race or gender have been identified for sofosbuvir, GS‑331007 or velpatasvir.</p><p><em>Elderly</em></p><p>Population pharmacokinetic analysis in HCV‑infected patients showed that within the age range (18 to 82&nbsp;years) analysed, age did not have a clinically relevant effect on the exposure to sofosbuvir, GS‑331007, or velpatasvir.</p><p><em>Renal impairment</em></p><p>A summary of the effect of varying degrees of renal impairment (RI) on the exposures of the components of Epclusa compared to subjects with normal renal function, as described in the text below, are provided in Table 19.</p><p>&nbsp;</p><p><strong>Table 19: Effect of Varying Degrees of Renal Impairment on Exposures (AUC) of Sofosbuvir, GS-331007, and Velpatasvir Compared to Subjects with Normal Renal Function</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p><strong>HCV-Negative Subjects</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HCV-Infected Subjects</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Mild RI</p><p>(eGFR &ge;50 and &lt;80 mL/min/1.73m<sup>2</sup>)</p></td><td rowspan="2" style="vertical-align:top"><p>Moderate RI</p><p>(eGFR &ge;30 and &lt;50 mL/min/1.73m<sup>2</sup>)</p></td><td rowspan="2" style="vertical-align:top"><p>Severe RI</p><p>(eGFR &lt;30 mL/min/1.73m<sup>2</sup>)</p></td><td colspan="2" style="vertical-align:top"><p>ESRD Requiring Dialysis</p></td><td rowspan="2" style="vertical-align:top"><p>Severe RI</p><p>(eGFR &lt;30 mL/min/1.73m<sup>2</sup>)</p></td><td rowspan="2" style="vertical-align:top"><p>ESRD Requiring Dialysis</p></td></tr><tr><td style="vertical-align:top"><p>Dosed 1 hr Before Dialysis</p></td><td style="vertical-align:top"><p>Dosed 1 hr After Dialysis</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir</p></td><td><p>1.6-fold&uarr;</p></td><td><p>2.1-fold&uarr;</p></td><td><p>2.7-fold&uarr;</p></td><td><p>1.3-fold&uarr;</p></td><td><p>1.6-fold&uarr;</p></td><td style="vertical-align:top"><p>~2-fold&uarr;</p></td><td><p>1.8-fold&uarr;</p></td></tr><tr><td style="vertical-align:top"><p>GS‑331007</p></td><td><p>1.6-fold&uarr;</p></td><td><p>1.9-fold&uarr;</p></td><td><p>5.5-fold&uarr;</p></td><td><p>&ge;10-fold&uarr;</p></td><td><p>&ge;20-fold&uarr;</p></td><td style="vertical-align:top"><p>~7-fold&uarr;</p></td><td><p>18-fold&uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Velpatasvir</p></td><td><p>-</p></td><td><p>-</p></td><td><p>1.5-fold&uarr;</p></td><td><p>-</p></td><td><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td><p>1.4-fold&uarr;</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>The pharmacokinetics of sofosbuvir was studied in HCV negative adult patients with mild (eGFR &ge;&nbsp;50 and &lt;&nbsp;80&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), moderate (eGFR &ge;&nbsp;30 and &lt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), severe renal impairment (eGFR &lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) and patients with ESRD requiring haemodialysis following a single 400&nbsp;mg dose of sofosbuvir, relative to patients with normal renal function (eGFR&nbsp;&gt;&nbsp;80&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>).&nbsp; &nbsp;&nbsp;GS‑331007 is efficiently removed by haemodialysis with an extraction coefficient of approximately 53%.&nbsp; Following a single 400&nbsp;mg dose of sofosbuvir, a 4&nbsp;hour haemodialysis removed 18% of administered dose.</p><p>In HCV-infected patients with severe renal impairment treated with sofosbuvir 200 mg with ribavirin (n=10) or sofosbuvir 400 mg with ribavirin (n=10) for 24 weeks or ledipasvir/sofosbuvir 90/400 mg (n=18) for 12 weeks, the pharmacokinetics of sofosbuvir and GS-331007 were consistent with that observed in HCV negative adult patients with severe renal impairment.</p><p>The pharmacokinetics of velpatasvir was studied with a single dose of 100&nbsp;mg velpatasvir in HCV negative patients with severe renal impairment (eGFR &lt;&nbsp;30&nbsp;mL/min by Cockcroft-Gault).&nbsp;</p><p>The pharmacokinetics of sofosbuvir, GS-331007, and velpatasvir were studied in HCV-infected patients with ESRD requiring dialysis treated with Epclusa (n=59) for 12 weeks, and compared to patients without renal impairment in the sofosbuvir/velpatasvir Phase 2/3 trials.</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of sofosbuvir was studied following 7‑day dosing of 400&nbsp;mg sofosbuvir in HCV‑infected adult patients with moderate and severe hepatic impairment (CPT Class&nbsp;B and C).&nbsp; Relative to patients with normal hepatic function, the sofosbuvir AUC<sub>0‑24</sub> was 126% and 143% higher in moderate and severe hepatic impairment, while the GS‑331007 AUC<sub>0‑24</sub> was 18% and 9% higher, respectively.&nbsp; Population pharmacokinetics analysis in HCV‑infected adult patients indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure to sofosbuvir and GS‑331007.</p><p>The pharmacokinetics of velpatasvir was studied with a single dose of 100&nbsp;mg velpatasvir in HCV negative adult patients with moderate and severe hepatic impairment (CPT Class&nbsp;B and C).&nbsp; Compared to subjects with normal hepatic function velpatasvir total plasma exposure (AUC<sub>inf</sub>) was similar in patients with moderate or severe hepatic impairment.&nbsp; Population pharmacokinetics analysis in HCV‑infected patients indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure to velpatasvir (see section&nbsp;4.2).</p><p><em>Body weight</em></p><p>In adults, body weight did not have a clinically significant effect on sofosbuvir or velpatasvir exposure according to a population pharmacokinetic analysis.</p><p><em>Paediatric population</em></p><p>Sofosbuvir, GS‑331007 and velpatasvir exposures in paediatric patients aged 12 years and older receiving oral once daily doses of sofosbuvir/velpatasvir 400&nbsp;mg/100 mg were similar to those in adults receiving once daily doses of sofosbuvir/velpatasvir 400&nbsp;mg/100&nbsp;mg.</p><p>The pharmacokinetics of sofosbuvir, GS‑331007 and velpatasvir in paediatric patients aged less than 12 years and weighing &lt;30 kg have not been established (see section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Sofosbuvir</u></p><p>Exposure to sofosbuvir in rodent studies could not be detected likely due to high esterase activity and exposure to the major metabolite GS-331007 was instead used to estimate exposure margins.</p><p>Sofosbuvir was not genotoxic in a battery of <em>in&nbsp;vitro</em> or <em>in&nbsp;vivo</em> assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and <em>in&nbsp;vivo</em> mouse micronucleus assays.&nbsp; No teratogenic effects were observed in the rat and rabbit developmental toxicity studies with sofosbuvir.&nbsp; Sofosbuvir had no adverse effects on behaviour, reproduction, or development of the offspring in the rat pre‑ and post‑natal development study.</p><p>Sofosbuvir was not a carcinogen in the 2‑year mouse and rat carcinogenicity studies at GS‑331007 exposures up to 15 and 9&nbsp;times, respectively, higher than human exposure.</p><p>&nbsp;</p><p><u>Velpatasvir</u></p><p>Velpatasvir was not genotoxic in a battery of <em>in&nbsp;vitro</em> or <em>in&nbsp;vivo</em> assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and <em>in&nbsp;vivo</em> rat micronucleus assays.</p><p>Velpatasvir was not carcinogenic in the 6-month rasH2 transgenic mouse and 2‑year rat carcinogenicity studies at exposures at least 50-times and 5-times higher than human exposure, respectively.</p><p>Velpatasvir had no adverse effects on mating and fertility.&nbsp; No teratogenic effects were observed in the mouse and rat developmental toxicity studies with velpatasvir at AUC exposures approximately 31‑ and 6‑fold higher, respectively, than the human exposure at the recommended clinical dose.&nbsp; However, a possible teratogenic effect was indicated in rabbits where an increase in total visceral malformations was seen in exposed animals at AUC exposures up to 0.7-fold the human exposure at recommended clinical dose.&nbsp; The human relevance of this finding is not known.&nbsp; Velpatasvir had no adverse effects on behaviour, reproduction, or development of the offspring in the rat pre‑ and post‑natal development study at AUC exposures approximately 5‑fold higher than the human exposure at the recommended clinical dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Copovidone</p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p><u>Film‑coating</u></p><p>Polyvinyl alcohol</p><p>Titanium dioxide</p><p>Polyethylene glycol</p><p>Talc</p><p>Iron oxide red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30<sup>o</sup>C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High density polyethylene (HDPE) bottle with a polypropylene child‑resistant closure containing 28&nbsp;film‑coated tablets with polyester coil.</p><p>Pack size of 1 bottle containing 28&nbsp;film‑coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Gilead Sciences Ireland UC
	IDA Business & Technology Park
	Carrigtohill
	County Cork
	Ireland
Tel: +353 (0) 21 483 5500
Fax: +353 (0) 21 483 5518
Email: csafety@gilead.com

	Ireland
Tel: +353 (0) 21 483 5500
Fax: +353 (0) 21 483 5518
Email: csafety@gilead.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2023

EUMAR21-ICGPS-AUG20-SAMAR23
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>